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Abstract
RECEPTOR TYROSINE KINASES-MEDIATED ACQUIRED PARP INHIBITOR RESISTANCE IN BREAST CANCER

Mei-Kuang Chen, B.S., M.S.
Advisory Professors: Dihua Yu, M.D., Ph.D. and Mien-Chie Hung, Ph.D.

Leveraging compromised DNA damage repair (DDR) pathways commonly
found in tumor cells, a classic strategy in cancer therapy is inducing excessive DNA
damage to cause cancer cell death. Small molecule poly(ADP-ribose) polymerase
(PARP) inhibitors (PARP-is) have been approved for clinical use in treating breast
cancer and ovarian cancer patients bearing DDR-deficient tumors with mutations in
breast cancer susceptibility genes (BRCAm). However, accumulating evidences
show that both intrinsic and acquired resistances to PARP-is exist in clinic and preclinical animal models. Therefore, I developed panels of cells with acquired PARP-is
resistance from PARP-is-sensitive triple negative breast cancer (TNBC) cell lines,
and used these cells to screen for common traits that can be targeted with feasible
therapeutic agent combinations to overcome PARP-is resistance. Since TNBC lacks
of effective targeted therapy so far, I focused on developing and using a panel of
PARP-is-resistant TNBC cells in this study. Among the molecular mechanisms
known contribute to PARP-is resistance, oncogenic kinase activations, including
several hyper-activated receptor tyrosine kinases (RTKs), are involved in enhancing
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DNA damage repair and decreasing affinity of PARP-is to PARP1. Among the candidate RTKs, MET has more small molecules inhibitors that can target it, and thus, my
colleagues and I made it a priority in investigating synergism between MET inhibitor
and PARP inhibitor in multiple cancer types and demonstrated that combinations of
PARP-is and MET inhibitors possess moderate to strong synergism in the different
cancer types we studied. In this thesis, I systematically screened for activated RTKs
as common traits in the PARP-is-resistant cells I developed. Through non-biased antibody array screening, I found MET phosphorylation is also high in the TNBC cells
with acquired PARP-is resistance. However, there are several activated RTKs have
higher prevalence than MET, including FGFR, EGFR and IGF1R. Therefore, in this
thesis, I extended my study from MET to other candidate RTKs and demonstrated
that MET is not the only RTK contribute to PARP-i-resistance in TNBC, and I found
that RTKs have different working mechanisms toward PARP-i-resistance. In conclusion, RTKs contribute to PARP-i-resistance through multiple mechanisms and it is
worthwhile to investigate these mechanisms to unveil more targeted therapeutic
strategies for cancer patients with PARP-i-resistance.
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Chapter I. Research Background

1. Subtypes of Breast Cancer
Breast cancer can be categorized into many subtypes according to the
molecular traits of cancer cells. Popular molecular traits used is expression of
hormone receptors for determining clinical hormone therapy’s treatment strategy, breast cancer can be group into different subtypes according to their hormone molecule expression status examined based on histology (reviewed in [1,
2]). Breast cancer that express estrogen receptor (ER) (ER-positive) or progesterone receptor (PgR) (PR-positive) are defined as hormone receptor positive
group. Around 70 % - 75 % of breast cancers belong to this hormone receptor
positive group, and expression levels of ER and PgR can be identified mainly
through immunohistochemistry (IHC) staining of tumor biopsy [1, 2]. Beside ER
and PgR, HER2 is another receptor commonly examined to classify breast cancer subtype due to distinct clinicopathologic feature and survival outcomes related to these receptors [1-4]. HER2 is a receptor tyrosine kinase (RTK) which
promotes cancer cell growth and can serve as prognostic factor [5, 6]. Approximately, around 15% of breast cancers express excessive HER2 receptor or having multiple copies of HER2 gene are group into HER2-positive subtype [1, 2].
HER2-positive breast cancer can be either hormone receptor positive or negative [4]. In clinical, HER2-positive subtypes is predominantly diagnosed by analyzing IHC and HER2 in situ hybridization results while HER2 phosphorylation
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status is a raising alternative defining method (reviewed in [7]). Beside the hormone-positive and HER2-positive subtypes, HER2-negative and hormone receptor negative breast cancers are group into triple negative breast cancer
(TNBC) [8]. In clinic, most of the hormone therapy targeted receptor positive patients are treated with targeted medications, such as tamoxifen or aromatase inhibitors, that specifically block hormone signaling or can reduce estrogen production [9, 10]. Most of HER2-positive patients will be treated with anti-HER2
agents such as trastuzumab (Herceptin), pertuzumab (Perjeta) or TDM1
(Kadcyla) [10]. Depends on the methods and threshold used for diagnosis and
on racial identities, around 10 - 25% of breast cancer are grouped into TNBC
subtype [11]. TNBC are generally more aggressive than other subtypes, which
has worst patient survival rate and rapid resistance to chemotherapy [3, 12].
However, because of lacking target for hormone receptor targeted therapy,
TNBC patients often are recommended with chemotherapy treatment instead of
targeted therapy [10, 12].
In addition to histological classification, a set of 550 genes were also be
used to classify breast cancers according to their molecular subtypes [2]. With
different gene expression clusters, breast cancer can also grouped into at least
five molecular subtypes: luminal A, luminal B, HER2-enriched, basal-like and
normal-like [2, 13]. For hormone-positive subtypes, most of breast cancers in
this group express gene profile as luminal breast epithelial cell [14], therefore, it
can also be referred as luminal type. Luminal type can be further divided into
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two groups: luminal A and B, where luminal B type expresses higher mitosis or
proliferation genes and higher lymph node involvement [15].

2. Transportation of Receptor Tyrosine Kinase into Cell Nucleus

This section is based upon the review article published in FEBS Journal. “Chen
MK, Hung MC. Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases. FEBS J. 2015 Oct;282(19):3693-721. PubMed PMID:
26096795; PubMed Central PMCID: PMC4591179.”

In the past, a majority of studies have focused on the canonical RTK signaling from cell surface via the following sequential events (Fig. 1): (1) The receptor binds with its ligand. (2) The receptor then undergoes conformational
changes and forms homo- or hetero- oligomers that are essential to activate the
kinase activity of the receptor. The tyrosine kinase domain then undergoes trans
autophosphorylation that greatly elevates the receptor’s catalytic activity. (3) The
phosphotyrosine residues serve as docking site for cytoplasmic adaptor proteins
containing Src homology-2 (SH2) and phosphotyrosine-binding (PTB) domain to
form signal transduction complex that determines and initiates the corresponding signaling cascade to regulate cellular processes in response to ligand stimulation [16-22].
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Figure 1. Canonical RTK signaling cascade
This figure illustrates the canonical RTK signal transduction pathway stepwise.
The canonical RTK signaling begins with (1) the receptor binding with its ligand.
(2) The receptors then undergo oligomerization and trans auto-phosphorylation.
(3) The phosphor-tyrosine residues on receptor served as docking sites for the
secondary messenger proteins containing either SH2 and/or PTB domain
(shown as green crescent-shape molecule) which are subjected to be phosphorylated by the RTK. (4) The secondary messenger proteins recruit and activate
its downstream proteins (illustrated as oval shape molecule) which serve as envoys delivering the signal into nucleus to regulate gene transcription.

4

Interestingly, members of the RTK subfamilies are also present in the nucleus and they are referred to as membrane receptor in nucleus or MRIN [23,
24]. Accumulating evidence indicates that at least 12 RTK families contain
MRINs that exist either as holoreceptor or truncated form with novel non-canonical functions in transcriptional regulation, cell proliferation, DNA damage repair
as well as cancer cell invasion [24-28]. In various cancer types, nuclear RTK expression is associated with poor prognosis [29-32]. Generally, after ligand-induced activation, membrane-bound MRINs are internalized from cell surface
through endocytosis and transported into the nucleus. However, RTKs can be
proteolytically cleaved to release an active RTK fragment that is also transported from the cell membrane to subcellular compartments, including the nucleus.

2.1. RTK internalization and endosomal retrograde trafficking to the Golgi
and ER
Cell surface receptors are also found in many subcellular compartments,
including the Golgi apparatus, mitochondria, ER, and nucleus. Upon ligand activation, RTK is rapidly internalized and translocated into endosomal compartments for signaling, recycling, or degradation by a clathrin-mediated or -independent pathways, depending on the different coat proteins in the membrane region that form the endocytic vesicles (reviewed in [33]). The endocytic vesicles
are then sent to different subcellular compartments based on the associated
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cargo proteins such as Rab proteins [34] or clathrin-binding adaptor proteins
(AP) [35] (Fig. 2).

Figure 2. Endosomal vesicle trafficking of internalized RTK.
The RTK are internalized through either clathrin-dependent or clathrin-independent pathways. In clathrin-dependent endocytosis mechanism, the internalized
membrane vesicle is coated with clathrin (green). Meanwhile, caveolin-mediated
endocytosis, which is the main clathrin-independent RTK endocytic mechanism,
is initiated at the membrane region that contain caveolin-rich lipid raft (purple).
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The endocytic vesicles from both pathways are sent to early endosome for sorting. Based on the component of coating proteins, the vesicles are then transported to different endosomal components, including recycle endosome, late endosome and trans Golgi network. Several important coating proteins that guide
vesicle transportation direction, including Rab proteins, clathrin-dependent
adaptor proteins (AP), retromer, syntaxin 6 (Syn 6), and Golgi-associated,
gamma adaptin ear containing, ARF binding protein (GGA) are indicated.

Clathrin-mediated endocytosis (CME) from the non-lipid raft membrane
domains is the predominant mechanism for RTK internalization. Prior to RTK activation, auto-inhibition of clathrin prevents the recruitment of cytosolic adaptor
protein. Upon RTK activation, clathrin recognizes specific posttranslational modifications, such as ubiquitination and acetylation, at the C-terminus of activated
RTK [36, 37]. The clathrin complex then recruits cargo-specific adaptors, e.g.,
AP2, which can also interact with phosphatidylinositol (4,5)-biphosphate (PIP2)
to bring in the phospholipids on adjacent plasma membrane and undergo conformational change that promotes the formation of clathrin-coated pit through
membrane curvature, clathrin polymerization, and internalization of the RTKcontaining pit from the plasma membrane [38]. Moreover, CME is a highly selective process that forms only after recognition of the cargo protein sequence by
AP. For example, AP2 specifically recognizes the YXXΦ and LL motif
([ED]XXXL[LI]) consensus sequence on the cargo protein (reviewed in [39]). In
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EGFR, the LL motif is important for AP-2 phosphorylation, which further facilitates the interaction between AP-2 and EGFR, and subsequent internalization of
EGFR via CME [40].
Posttranslationally modified RTKs, such as from ubiquitination, can also
be internalized for transport to various compartments but the process occurs via
a clathrin-independent endocytic pathwya [41]. There are several clathrin-independent endocytic mechanisms, including phagocytosis, macropinocytosis, and
lipid raft-mediated (e.g., caveolin-mediated) endocytosis, and among them,
macropinocytosis and lipid raft-mediated endocytosis are more common in RTK
internalization. Macropinocytosis is a growth factor-induced and actin-mediated
transient endocytic process that begins from all membranous regions such as
those of the lipid rafts in larger vesicles containing extracellular fluid and plasma
membrane-bound components. Unlike clathrin-dependent endocytosis, caveolae-mediated endocytosis does not require a specific coat protein and is usually
associated with lipid raft membrane regions containing caveolin-1 protein (reviewed in [42]). Recently, Boucrot et al. reported a new clathrin-independent endocytic mechanism called endophilin-mediated endocytosis (FEME) which does
not required AP2 or clathrin [43]. Renard et al. further showed the FEME uses
endophilin-A2 as membrane scissor to release the endocytic vesicles [44]. Endocytosis of membrane receptors, including RTKs such as EGFR, MET,
VEGFR, PDGFR, IGF-1R, and TrkA via FEME requires ligand activation [43].
The binding of endophilin by CIN85 and Cbl are important in FEME, further sup-

8

porting that RTKs are subjected to FEME after ligand-induced activation. However, take EGFR for example, the EGFR FEME is observed mainly under high
concentration EGF treatment, and FEME was suggested to more related to RTK
canonical signaling down regulation [43].
After RTK internalization, the receptors are routed to the early endosomes, where the fate of cargo is determined. In general, RTKs can be degraded or recycled or can undergo retrograde trafficking to the Golgi apparatus
(Fig. 2). Although it has been reported that in EGFR is recycled after stimulation
by high concentrations of ligand in A431 cells, which express high levels of
EGFR with 80% of EGFR internalized [45], not all endocytic receptors are subjected to recycling or degradation. Instead, a small portion of them undergoes
retrograde transport which is the influx of protein and lipid from cell surface to
Golgi or from Golgi to ER. The trans Golgi network (TGN)-targeting coat proteins, including Rab9, syntaxin 6, and GGA, guide fusion of the endosomal vesicle with TGN [46]. Du et al. demonstrated that inhibition of dynein or knockdown
of dynein or syntaxin 6 attenuates EGFR accumulation in the Golgi apparatus
and nucleus [47]. These findings indicated that the EGFR detected in these subcellular compartments is from the cell surface. Many reports have indicated that
internalized RTKs via CME can also be transported to TGN for further sorting
through coated vesicle transport, including EGFR [47], c-MET [48], and fibroblast growth factor receptor (FGFR)-1 [49, 50]. However, endocytic RTKs that
undergo retrograde transport do not necessarily stop at TGN as they can be fur-
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ther routed back to the ER and even the nucleus. In general, COPI vesicles mediate retrograde transport between the Golgi network and ER as exemplified by
the Golgi-to-ER translocation of EGFR [50].

2.2. Nuclear trafficking of MRINs from ER
After reaching ER, the endocytic RTKs can be further transported into the
nucleus via two importin-β-mediated pathways, integral trafficking from the ER
to the nuclear envelope transport (INTERNET) and integrative nuclear FGFR-1
signaling (INFS) (Fig. 3) [51]. The major difference between the two is that the
receptor remains membrane bound and is localized to inner nuclear membrane
(INM) before nuclear translocation in INTERNET whereas FGFR-1 becomes a
soluble protein after its release from ER or ER-derived membrane vesicle before
translocation into the nucleus in INFS [51].
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Figure 3. Retrograde and nuclear transportation mechanisms of membrane-bound RTKs.
The RTKs are retrograde transported from Golgi to ER through COPI-coated
vesicles. The ER to nuclear transportation are divided into two pathways, INFS
and INTERNET. For the INFS pathway, the RTK are pumped through Sec61
complex into cytosol where it binds to cytosolic Importin complex and transported into nucleus by the importin-NPC interaction. For the INTERNET pathway, the RTK are trafficking along ER and translocate from ONM to INM through
NPC by binding with ER-associated Importin, and the RTK were released from
INM by Sec61 complex into nucleoplasm. For both pathways, the nuclear localized RTK can interact with transcription factors and functions as transcription
regulator.
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Both EGFR and ErbB-2 contain a typical NLS that attracts NLS-harboring
molecules and form complex with importin-β [52]. It has been shown that EGFR
and ErbB-2 are transported from the ER to the outer nuclear membrane (ONM)
and then to the NPC where the receptors enter the INM with the help of importin-β [51, 53]. As demonstrated with digitonin-permeabilized cells, detection
of importin-β in the non-nuclear extract suggest that the INTERNET mechanism depends on membrane-associated importin-β to transport EGFR and
ErbB-2 from the ONM into the INM [51, 54]. As demonstrated by Wang et al.,
Sec61β translocon is required for releasing INM-bounded EGFR into the nucleus [55]. Because EGFR and ErbB-2 both contain NLS which can interact with
membrane-bound importin-β, we hypothesized that INTERNET pathway predominantly mediates nuclear translocation of NLS-containing RTKs. Given that
NLS is conserved among most of RTKs and that nuclear translocation of another NLS-containing RTK, c-MET, also follows the INTERNET pathway (unpublished data), it is likely that INTERNET is more commonly shared mechanism for RTK nuclear trafficking. However, further investigation of the nuclear
transport mechanism of other RTKs is required to define this notion.
Via the INFS pathway, FGFR-1 is released as soluble protein from ER or
ER-derived membrane vesicle into the cytosol through the Sec61 channel.
FGFR-1 then associates with importin-β in cytoplasm before being transported
into the nucleus [56]. Notably, even though FGFR-1 does not contain a consensus NLS sequence, it can still translocate into the nucleus by association with
NLS-containing proteins, such as NLS-containing ligand, FGF-2 [56].
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3. Regulation of Therapeutic Resistance in Cancers by Receptor Tyrosine Kinases

This section is based upon the review article published in American Journal of Cancer Research. “Chen MK, Hung MC. Regulation of therapeutic resistance in cancers by receptor tyrosine kinases. Am J Cancer Res. 2016 Mar
15;6(4):827-42. eCollection 2016. PubMed PMID: 27186434; PubMed Central
PMCID: PMC4859887”

DNA damage stimuli can be divided into two classes, endogenous and environmental, based on the site of the stimulus’ origin [57]. Endogenous DNA
damage generates chemical changes in DNA structure leading to mutagenic
events such as deamination of bases resulting from hydrolytic and oxidative
events inside the cell. Environmental DNA damage can result from either physical or chemical agents outside the cells [57]. The incidence of DNA damage occurs frequently in normal cells. It is estimated that the error rate of the DNA replication machinery is at least 10–8 in Escherichia coli and human [58, 59]. In addition to replication errors, DNA breaks mainly caused by reactive oxygen species (ROS) are estimated to be 105 events per day [60, 61]. Thus, DNA damage
response (DDR) is required to correct mistakes in DNA and is also responsible
for eliminating cells with irreparable deleterious damage.
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DNA damage and DDR are highly related to the formation and treatment
of cancer. During carcinogenesis, the inefficiency and infidelity of the DDR pathway are the main causes of oncogenic events, such as DNA mutations, translocations, and epigenetic modifications, which correlate DDR to cancer risks [57,
62-65]. In cancer treatment, both radiotherapy and chemotherapy utilize DNA
damaging agents that eliminate cancer cells by inducing DDR. Capitalizing on
the deficiency of DDR in cancerous cells, the treatment of cancer with DNA
damaging agents is an effective means of inducing massive DNA lesions and
programmed cell death in the cells unable to resolve the damage. However, resistance to these types of treatment is reported in patients, and the crosstalk between DDR and altered receptor tyrosine kinase (RTK) signaling pathways in
solid tumors is thought to be an important contributor to the development of
chemotherapy resistance [66-69]. Overexpression of RTKs also contributes to
tumor progression through promotion of cell survival, metastasis and stimulation
of angiogenesis [70]. While many inhibitors targeting RTKs are already in clinical
trials or clinical use [70], it is important to understand how RTKs promote cell
survival upon DNA damage to develop combination therapies to enhance treatment efficacy.

3.1. DNA damage response
Once the DNA damage sensor protein machinery detects DNA damage
lesions, it recruits mediators and numerous transducer and effector proteins to
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ensure that the transcription and translation processes are paused by cell cycle
arrest and to initiate DNA damage repair or apoptosis (Fig. 4 and Table 1) [57].

Figure 4. DNA damage reagents and DNA damage response.
DNA is vulnerable to both exogenous and endogenous DNA damage reagents,
including replication error, replication inhibition, ultraviolet (UV) light and cancer
treatments such us irradiation therapy and chemotherapy. Exposure to these
DNA damage reagents leads to DNA damage including DNA single-strand
break (SSB), DNA inter strand cross-linking (ICL), DNA double-strand break
(DSB) as well as single strand DNA lesion (ssDNA). The DNA damage lesions
then trigger the signal cascade which results in DDR primarily through delayed
cell cycle from G1 to S phase (G1/S arrest) or from G2 to M phase (G2/M arrest)
and as well as triggering DNA damage repair pathways. After successfully repaired, the cell cycle arrest is released and the cells will survive. However, the
severe DNA damage adducts or DNA damage repair failure will eventually leads
to apoptotic cell death.
15

Table 1. Sources of DNA damage and major repair pathways

The main mediators in DDR pathways are members of the phosphatidylinositol 3-kinase-like protein kinases family, including ataxia-telangiectasia mutated (ATM), ATM and Rad 3-related (ATR), and DNA-dependent protein kinase
(DNA-PK). When DNA damage lesions are recognized by a sensor protein,
these mediators are recruited to the damage site and phosphorylate downstream proteins that are involved in all aspects of DDR. In addition to these mediators, poly (ADP-ribose) polymerases (PARPs), a large enzyme family with
multiple functions, also play important roles in DDR [71, 72]. PARP1 and PARP2
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are activated by DNA single-strand break (SSB) and DNA double-strand breaks
(DSB) and can poly(ADP-ribos)ylate (PARylate) different substrates under different genotoxic stress to further elevate DDR response [73].
3.1.1. Cell cycle arrest
The cell cycle is subdivided into G1, S, G2, and M phase. In brief, cells increase in size and prepare for DNA synthesis during G1 phase and undergo
DNA replication during S phase. Then, cells continue to grow and prepare for
mitosis in G2 phase before dividing in M phase. To ensure genomic stability, eukaryotic cells develop cell cycle checkpoints that pause cell division in response
to environmental stress, DNA damage, and improper DNA replication [74]; this
process is referred as cell cycle arrest. In mammalian cells, there are two major
signaling pathways that control cell cycle arrest in response to DNA damaging
stress: the ATM pathway, which is responsible for DSB throughout the cell division cycle and the ATR pathway, which is responsible for both DSB as well as
replication forks [74, 75].

3.1.2. DNA damage repair and therapeutic DNA damaging agents
In 1974, researchers had already realized that the integrity of DNA is vulnerable and that the repair mechanisms are crucial to maintain genomic stability. Dr. Francis Crick stated in The double helix: a personal view that “… one
could hardly discuss mutation without considering repair at the same time” [76].
The DNA damage repair pathways are composed of base excision repair (BER),
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nucleotide excision repair (NER), mismatch repair (MMR), single-strand annealing (SSA), homologous recombination repair (HR) and non-homologous end
joining repair (NHEJ) [57].
3.1.2.1.

Repair of base alternation and small DNA damage adducts

Base alternation and small DNA damage adducts, covalent DNA-chemical
binding structures, can be caused by low concentration of reactive oxygen species (ROS) as well as alkylation agents and DNA crosslinking agents. Small
DNA damage adducts can be easily repaired in normal cells compared with
DSBs, but the failure to repair these adducts’ fidelity may lead to oncogenic mutations. In cancer treatment, low doses of ionizing radiation (IR) and low linear
energy transfer γ-radiation [77] can generate low concentrations of ROS
whereas a large number of chemotherapeutic drugs are alkylating agents, including nitrogen mustards (mechlorethamine, cyclophosphamide, and
ifosfamide), nitrosourease (streptozocin, carmustine and lomustine), alkyl sulfonates (busulfan), triazine (dacarbazine and temozolomide) and ehylenimines
(thiotepa and altretamine) [78].
Base excision repair. BER is mainly responsible for small lesions caused
by endogenous DNA damage, such as oxidation, hydroxylation, deamination, or
methylation, and is considered to be the most frequently used DNA damage repair pathway [57, 79]. Abnormal DNA bases are detected and excised by lesionspecific DNA glycosylases, such as OGG1 and MYH, creating apurinic, apyrimidinic, or abasic sites (AP sites) [57]. For AP sites limited to a single base, the
short patch BER endonuclease APE1 generates a single nucleotide gap at the
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AP site and recruits DNA polymerase β as well as XRCC1-DNA ligase to fill the
gap. For extensive AP sites (2-10 bases), long patch BER with FEN1 endonuclease and proliferating cell nuclear antigen (PCNA)-DNA polymerase δ/ε complex are used to repair the lesions [57]. Genetic variants of ADPART, XRCC1,
APE1 proteins in BER are reported to increase the risk of squamous cell carcinoma [80, 81] and bladder cancer [82]. APE1 and XRCC1 polymorphisms have
been reported to correlate with gastric cancer [83] and with risk of lung adenocarcinoma [84, 85], respectively. The nitrogen (N-) and oxygen (O-) alkylated
DNA bases caused by alkylating agents as well as oxidative DNA bases induced by ROS are repaired by BER [86].
PARP participates in many DNA repair pathways including BER, NER, HR
and NHEJ [87, 88] but predominantly functions in the BER pathway. Although
PARP is not essential in the BER pathway, the treatment of PARP inhibitor has
successfully converted the base lesion into a SSB [89], which is a more severe
type of DNA damage that can be developed into lethal DSB lesions during DNA
replication [71, 90]. PARP inhibitors, for example, olaparib, can induce synthetic
lethality in DSB repair-deficient cancer cells, such as BRCA-mutated cells, and
benefit patients with BRCA1/2-mutated breast or ovarian cancer [71, 91-93].
Nucleotide excision repair. NER mainly tackles a variety of helix-distorting lesions that impede transcription and replication by interfering with base
pairing [57, 79]. Global genome NER (GG-NER) repairs helix-distorting lesions
and prevents mutagenesis. Transcription-coupled NER (TC-NER) repairs transcription-blocking lesions to prevent perturbed gene transcription. The damage
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recognition steps are different between these NER mechanisms: in GG-NER,
the lesions are detected by XPC/hHR23B and XPE protein complex, whereas
the RNA polymerase/CSA/CSB/HMGN1 protein complex is responsible for lesion detection in TC-NER [57]. After lesion recognition, XPA proteins are recruited and bind to DNA around 20 base pair upstream of the DNA damage adduct. The DNA double helix around the DNA damage adduct is then unwound
by a multi-protein complex, TFIIH. Single-stranded DNA (ssDNA) resulting from
the unwinding process is stabilized by the RPA protein, and the DNA adduct excision steps are completed by the XPF-ERCC1 and XPG proteins. NER repairs
DNA lesions caused by various endogenous and environmental DNA damaging
agents, including UV irradiation [94], platin-based chemotherapy drugs, e.g., cisplatin and carboplatin [95], and carcinogens, such as benzopyrene [96]. Defects
in NER result in diseases, such as xeroderma pigmentosum (XP), Cockayne
syndrome, and trichothiodystrophy [57]. Among the NER-related diseases, XP
patients, but not Cockayne syndrome or trichothiodystrophy patients, exhibit a
higher incidence of skin cancer. For example, XP group A patients, a subpopulation of XP patients, are more prone to basal cell and squamous cell carcinoma, and melanoma [97, 98].
Mismatch repair. MMR is designed to resolve mispaired or modified bases as well as insertion or deletion loops. Heterodimers of the MSH2/MSH6
complex recognize mismatched pairs and single-base loops whereas the
MSH2/MSH3 complex recognizes insertion/deletion loops. This damage recog-
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nition complex then recruits and interacts with MLH1/PMS2 and EXO1 endonuclease to excise the newly synthesized strand after mismatch/loop. DNA is then
resynthesized by PCNA, RPA, and DNA polymerase δ/ε complex [57]. Germline
mutations in MLH1 and MSH2 have been shown to contribute to hereditary nonpolyposis colorectal cancer [99], and defects in MSH6 are known to cause atypical hereditary non-polyposis colorectal cancer. Germline variants in DNA polymerase ε are also associated with MMR-deficient colorectal cancer [100]. MMR
deficiency testing can predict the prognosis of colorectal cancer and stratify patients for adjuvant chemotherapy [101].
3.1.2.2.

Repair of DNA double-strand breaks

DSBs are considered to be lethal DNA damage lesions that must be repaired before cell continues to grow and proliferate. Currently, radiotherapy and
most chemotherapies aim at creating irreparable DSBs in cancerous cells. In
cancer treatments, radiotherapies, such as ionizing radiation, induce high concentrations of ROS [77]. Topoisomerase poisons, such as doxorubicin and
daunorubicin, can cause DSBs [102].
Non-homologous end joining (NHEJ). NHEJ is important for DSB repair
in DNA damage repair as well as for V(D)J recombination in T and B cells [103].
NHEJ functions in DSB repair throughout the cell cycle, especially in G0/G1
phase, and is highly conserved from prokaryotes to eukaryotes, demonstrating
its mechanistic flexibility and tolerance for various structures of DNA ends [104106]. NHEJ is a highly mutagenic repair pathway in that it ligates two ends at the
DSB site together regardless of the homology of the DNA sequence [106].
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NHEJ can be divided into two pathways, canonical NHEJ (C-NHEJ) and alternative NHEJ (A-NHEJ), according to the resection of DNA ends at the breakage
site and the proteins involved [103]. For C-NHEJ, Ku proteins bind to the broken
ends of DSBs and recruit DAN-PK as well as 53BP1 and the Mre11 complex to
the damage site. The breakage sites are then processed by Artemis and are
simply ligated in cis by the XRCC4/Ligase IV/XLF complex [103]. The direct ligation process in C-NHEJ alters the DNA sequence at the damage site, resulting
in more mutations as extra nucleotides are excised before ligation. For A-NHEJ,
the DNA breakage ends are recognized by PARP1, which recruits the Mre11
complex to the damage site before a few nucleotides are excised by CtIP-mediated end resection. The gap can then be filled and ligated by the XRCC1/Ligase
III/Ligase I complex [103].
Homologous recombination repair (HR). HR repair is the predominant
type of DSB repair that occurs in late S and G2 phases of the cell cycle [107].
The HR pathway utilizes a DNA template strand with significant sequence homology to the damaged strand; therefore, this repair pathway is considered to
be error-free and non-mutagenic [57]. The regulation and flexibility of the Mre11
nuclease activities are important in controlling the repair pathway choice during
DSB repair [108]. The HR pathway initiates binding of the Mre11-Rad50-Nbs1
protein complex (MRN) to the DSB site and the cyclin-dependent kinase (CDK)dependent activation of the CtIP protein, which regulates Mre11-mediated end
resection of DNA [108, 109]. After initial resection, the Exo1-DNA2-Sgs1 complex is responsible for further DNA resection, and the ssDNA is protected by the

22

RPA proteins [107]. The RPA proteins are then replaced by Rad51 in a
BRCA1/BRCA2 dependent strand invasion process, and the pairing of homologous sequence is completed and extended with the help of Rad52, Rad54 and
WRN complex proteins [110]. The junctions at homologous pairing site are then
resolved by the BLM/TOPIII/Mus81 complex [110].
Cancer cells are highly proliferative and divide more frequently than cells
in normal tissue. Genomic integrity in S and G2 phase is required before cells
divide; therefore, inhibiting HR and initiating DSB in HR-deficient cells are both
efficient ways to inhibit cancer cell proliferation by trapping cells in the G2/M cell
cycle checkpoint. Chemicals that serve as HR inhibitors are often involved in
regulating protein expression, nuclear localization, and recruitment of HR proteins. For example, inhibitors of histone deacetylation and HSP90 can block HR
by diminishing the expression of BRCA2 [111] and Rad51 [112]. There are also
cancer cells that have HR-deficiency. For example, BRCA1/2 germline mutations are reported in many patients with solid tumors, especially in hereditary
breast and ovarian cancer patients [113, 114]. The deficiency of HR leads to
sensitization of patients to DNA damaging agents such as cisplatin and PARP1
inhibitors [115-119].
Single-strand annealing. SSA is an error prone repair mechanism that is
initiated when DSBs occur between two repeated intra-strand DNA sequences.
The ERCC1/XPF complex is responsible for the DNA excision step in SSA
[120]. After excision of the 5´-ends and exposing regions of homology, the homologous strands of DNA must be paired through SSA, as in HR. Unlike HR,
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the RAD52 and RAD59 proteins play a predominant role in the SSA DNA binding step instead of RAD51 [121]. SSA is reduced in G1-arrested cells, but it is
not clear whether the SSA pathway is cell cycle dependent because it is not under control of ATM, ATR, or DNA-PK [120]. Although SSA utilizes homologous
pairing of repeated DNA sequence, it excises the repeated sequence closer to
the site of the DNA break and could be mutagenic. However, the detailed mechanism and regulation of SSA is still unclear. Therefore, the importance of SSA in
cancer formation and progression cannot be clearly addressed at this point in
time.

3.2. Regulation of RTK signaling on DDR and therapeutic resistance
Mutations in the RTKs as well as dysregulation of its downstream signaling proteins can impair normal DDR. Some RTKs are reported to translocate
into the nucleus and their nuclear substrates includes DDR related, RTKs have
been implicated in DDR regulation as the canonical RTK downstream proteins
have been shown to correlate with DDR regulation (Fig. 5). RAS constitutive activation and/or mutation are observed frequently in human cancers, and the KRAS encoding gene is particularly vulnerable to chemical carcinogens [122,
123]. Oncogenic activation of K-RAS leads to an accumulation of replication
stress by orchestrating wild-type H- and N-RAS signaling, and triggers the
ATR/Chk1 pathways to evade G2 cell-cycle arrest [124]. Oncogenic K-RAS also
promotes A-NHEJ by upregulating the expression of DNA ligase III, PARP1, and
XRCC1 in leukemia cancer model [125]. The AKT-mediated signaling pathway
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also regulates DDR. It has been reported that when cells are pretreated with
Chk1 inhibitor, inactivation of AKT/PKB pathway can restore radiation-induced
Chk1 activation at late G2 cell cycle arrest [126]. Other than Chk1, AKT is
known to inhibit TopBP1 and BRCA1 even though it also positively regulates
ATM, ATR, and DNA-PK (reviewed in [127]). In addition to the RAS and AKT
pathways, some RTKs can also regulate DDR through other pathways as discussed in the following sections.

Figure 5. RTKs mediate DDR through canonical AKT and RAS pathways.
In general, RTKs can activate both AKT and RAS pathways. Crosstalk between
these two pathways can occur through AKT-RAF and ERK-GAB interactions.
The downstream effects of the AKT pathway include inhibition of apoptosis
through BAD and p27, inhibition of cell cycle progression through Chk1, downregulation of DNA damage repair through BRCA1, and indirect upregulation of
DNA damage repair through ATM, ATR and DNAPK. Meanwhile, RAS itself can
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activate cell cycle arrest through ATR and Chk1 while promote DNA damage repair through expression of DNA ligase III, PARP1 and XRCC1. Also, the downstream of RAS pathway can activate ATM to promote DDR.

3.2.1. Regulation of DDR by the ErbB family
The ErbB family is composed of four receptors, ErbB1 (epidermal growth
factor receptor, EGFR), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4).
Among them, EGFR and HER2 have been shown to regulate DDR and contribute to therapeutic resistance through both canonical and non-canonical signaling pathways. Using EGFR siRNAs and EGFR small molecule inhibitors, Wei et
al. demonstrated that EGFR-mediated AKT/ERK pathway upregulates cell cycle
regulatory proteins, including cyclin A, B, E, and CDK 1/2, in carcinogenic metalinduced proliferation of triple-negative breast cancer cells (Fig. 6) [128]. The
RAS/MEK/ERK pathway promotes EGFR-mediated radioprotection [129] by affecting gene transcription of the DNA repair proteins. The expression levels of
the base repair DNA ligase XRCC1 and the DNA adduct excision protein
ERCC1 upregulated under radiation treatment can be attenuated by EGFR inhibitor [130, 131]. By utilizing small molecule inhibitors, radiation-induced and
EGFR-mediated XRCC1 upregulation was shown to depend on the
RAS/MEK/ERK pathway whereas normal XRCC1 expression is affected by
EGFR-mediated PI3K/AKT pathway (Fig. 6) [132].
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Figure 6. Some RTKs regulate DDR through specific canonical pathways.
The chemical-induced EGFR activation will activate AKT pathway to upregulate
the expression of cyclin A, B, E and CDK 1, 2 to promote cell cycle. On the other
hand, the radiation-induced EGFR activation will activate RAS pathways to increase expression of XRCC1 and ERCC1 in cancer cells. MET can downregulate the expression of AIF specifically through the FAK pathway. Ron promotes
PCNA Y211 phosphorylation through c-ABL mediated pathway.

Nuclear EGFR also plays an important role in DNA damage repair, including MMR, NHEJ and HR (Fig. 7). For instance, nuclear EGFR can phosphorylate histone H2B and histone H4. Specifically, EGFR phosphorylates histone H4
at Y-72 to regulate histone H4 methylation [133]. EGF, as well as arsenic, can
stimulate nuclear EGFR-mediated phosphorylation and stabilization PCNA via
Y211. Phosphorylated PCNA Y211, which has been shown to correlate with
poor patient survival, promotes cell proliferation as well as inhibits the endonuclease activity of MutLα, which leads to inhibition of MMR [66, 134, 135]. Yu et
al. demonstrated that PCNA-derived peptide blocks the EGFR-PCNA complex
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and suppresses the growth of breast cancer cells [136]. Nuclear EGFR plays a
role in HR in many aspects. EGFR phosphorylates ATM at Y370; depletion of
EGFR abolishes ATM-mediated foci formation and HR; the ATM-EGFR interaction can be blocked by gefitinib, an EGFR inhibitor [137]. EGFR also interacts
with BRCA1 to facilitate HR; the EGFR-BRCA1 interaction as well as BRCA1
nuclear translocation can be blocked by the EGFR inhibitor, lapatinib [138].
These interactions provide molecular basis for the combination therapy of EGFR
inhibitor with PARP inhibitor, which induces synthetic lethality in tumor cells, as
demonstrated in breast and ovarian cancers [138-140]. Radiation also enhances
EGFR nuclear translocation [141, 142]. Nuclear accumulation of EGFR contributes to radio-protection and interferes with DNA repair through interacting and
regulating activity of DNAPK [143-146]. Treatment of EGFR monoclonal antibody, cetuximab (C225), promotes the interaction between EGFR, DNAPK, and
Ku proteins, which results in a redistribution of DNAPK from the nucleus to cytosol, a critical step in the radiosensitizing role of EGFR blockade [147-149].
EGFR blockade also inhibits cell growth via p27 and maintains cells in G1
phase, which has been shown to also contribute to the radiosensitizing effect of
EGFR [150, 151]. In addition to EGFR, HER2 also regulates cell cycle regulation by binding to and colocalizing with cyclin B-bound CDC2 protein. Phosphorylation of CDC2 by HER2 at Y15 then delays entry of cells into M phase and
contributes taxol resistance in HER2-overexpressing cancer cells [152]. Inhibition of HER3 also sensitizes cancer cells to radiation therapy by blocking AKT
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phosphorylation [153], and dual inhibition of EGFR and HER3 can overcome
cross-resistance to EGFR inhibition and radiation [154, 155].

Figure 7. EGFR also mediates DDR through non-canonical signaling pathways.
EGFR interacts with BRCA1 and DNAPK to promote their translocation into the
nucleus. EGFR can also phosphorylate histone, ATM and PCNA to promote histone methylation, foci formation, and proliferation whereas EGFR-mediated
PCNA phosphorylation inhibits MutL activity.
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3.2.2. MET family regulated DDR
Two RTKs in the MET family, MET (also known as hepatocyte growth factor (HGF) receptor) and Ron (also known as macrophage stimulating 1 (MST1)
receptor) also regulate DDR. In lung adenocarcinoma, HGF-induced MET activation inhibits apoptosis through the canonical pathway. Chen et al. demonstrated that the FAK–/– mouse embryonic fibroblast cells express higher levels of
apoptosis-inducing factor (AIF), which correlates with better therapeutic response to cisplatin treatment. Moreover, AIF expression and cisplatin sensitivity
were increased in cells when binding of MET to FAK was impeded or when MET
inactivated [156], suggesting that this FAK-regulated AIF expression is downstream of MET signaling in lung adenocarcinoma cells. MET is also reported to
directly phosphorylate PARP1 at Y907 site [157]. Phosphorylated PARP1 is
more resistant to the PARP inhibitor, veliparib, and the combination of MET inhibitor and veliparib increased breast cancer cell killing effect. Contrary to MET,
Ron phosphorylates PCNA at Y211 through the canonical signaling pathway by
activating Ron downstream kinase, c-Abl, an adaptor protein containing SH2 domain [158]. These findings suggested a functional redundancy between Ron receptor and nuclear EGFR on PCNA Y211 regulation.

4. PARP Inhibitors in Cancer Therapy
4.1. PARP Protein Family
Poly (ADP-ribose) polymerase (PARP) is an enzyme family contains 18
members with sequence homology in their catalytic domain. The structure of
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PARP1 (113 kDa) contains 2 zinc-finger domains (ZnF I and II), a zinc binding
domain (ZnFIII), BRCA1 C-terminal homology domain (BRCT), WGR domain
and catalytic domain (CAT) (Fig. 2). PARP1 and PARP2 are activated immediately by DNA strand breaks. Single strand DNA (ssDNA) damage recognition
step needs cooperation of both ZnFI and ZnFII domains of PARP1. PARP1
weakly interacts with and diffuses 3 dimensionally through undamaged DNA by
its ZnFI domain to screen for damaged DNA, the discontinuity of ssDNA will allow additional PARP1-DNA binding through ZnFII domain of PARP1. ZnFII domain exhibit higher DNA-binding affinity than ZnFI, and the DNA-bounded ZnFI
and ZnFII domains can form a heterodimer with ZnF1 and 2 domains from a
second PARP1. After the formation of PARP1 dimer, one of the PARP1 can
trans-autoPARylate the other PARP1 to activate its enzymatic activity. It is also
reported that when encountering double strand DNA (dsDNA) breaks, PARP1
can interact with broken DNA with its ZnFI, ZnFIII and WGR domains [159]. The
conformational change of PARP1 when binding to broken DNA will distort its
CAT domain, and the destabilized CAT domain will increase its catalytic activity[160]. Although PARP participates in many DNA repair pathways, including
BER, NER, HRR and NHEJ, it functions predominantly in the BER pathway [87,
88].
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Figure 8. Domains of human PARP1 and PARP2 proteins.
Human PARP1 is a 113 kDa protein with 4 major domains including ZnF, BRCT,
WGR and catalytic domains. PARP1 ZnFI to ZnFIII compose its N-terminal DNA
binding domain. PARP1 also have nuclear localization sequence (NLS) in its Nterminal to lead the protein imported into cell nucleus. PARP2 is a 66 kDa protein with N-terminal DNA binding domain containing NLS, WGR and catalytic
domain.

The enzymatic function of PARP1-5 is to post translationally poly(ADP-rybosyl)ate (PARylate) target proteins by consuming nicotinamide adenine dinucleotide (NAD+) and transfer its negative charged ADP-ribose (ADPr) onto
PARP’s target proteins. While PARP6-8, PARP10-12 and PARP14-16 can only
mono-ADP-rybosylate (mARylate) target proteins; PARP9 and 13 are most likely
to be catalytic inactive. The biological process affected by PARP largely depends on the function of its target proteins. Among PARP family, functions of
PARP1 and PARP2 in DNA damage repair (DDR), chromatin modification, transcription regulation, cell death and inflammation regulation are most studied.
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4.2. PARP1 and PARP Inhibitors in DNA Damage Response
When encountered structures of DNA breaks, PARP1 PARylates multiple
DNA repair proteins including itself [160, 161]. In BER, PARP1 and PARP2-mediated PARylation facilitates recruitment of XRCC1 to DNA breaks and thus enhance repair efficiencies [161]. PARylated PARP1 also recruits DNA damagebinding protein 1 (DDB1)–DDB2 complex to bulky adducts of DNA to facilitate
lesion detection for GG-NER [161]. Beside SSB repair mechanisms, PARP1
also plays a role as DNA break sensor in DSB repair through interacting with
MRE11 and ATM proteins [161]. PARP1 recruits MRE11 to DSB sites, and it
may also indirectly participated in BRCA1 recruitment by interacting with
BRCA1-associated RING domain protein 1 (BARD1) to facilitate HR repair
[161]. The PARP1 and MER11 interaction can also stimulate alternative NHEJ,
a repair mechanism which utilizes microhomology between two strands at DSB
region and using sequences around the microhomology sites as template to fill
DNA gaps with DNA polymerase θ [161]. In conclusion, PARP1 plays important
roles in both SSB and DSB repairs.
Small molecule PARP inhibitors (PARP-is) were developed as therapeutic
agents for cancer treatment, because the deficiencies in DNA repair results in
one of the hallmarks for cancer [162]. Among the PARP-is, at least three of
them, olaparib, rucaparib, and niraparib, are approved by the United States
Food and Drug Administration for treating BRCA1/2-mutated (BRCAm) ovarian
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cancer as single therapeutic agent or for maintenance support for platinum-sensitive patients [163]; two of them, olaparib and talazoparb, were approved for
BRCAm breast cancer treatment [164]. PARP-is are designed to compete with
NAD+ for catalytic pocket of PARP1 and, therefore, PARP-is can inhibit PARP1
PARylation activity [165]. Beside of inhibiting PARP1 enzymatic activity, most of
the PARP-is can also immobilize PARP1 on damaged DNA, a phenomenon
known as “PARP trapping” [166]. Because cytotoxicity of the PARP-is are not
positively correlated to their capability of enzymatic inhibition, but more correlated to their capability of inducing PARP trapping, PARP trapping is considered
as main working mechanism of PARP-is in eliminating DDR-deficient cells [166].
Repairing the PARP trapping-caused PARP1-DNA complex requires multiple
DNA repair pathways. Deficiencies in either HR, topoisomerase, Fanconi anemia pathway, DNA polymerases, or NER can increase PARP-is sensitivities in
cells [167]. Therefore, although PARP-is have currently be approved for BRCAm
cancer treatment, these PARP-is may be effective targeted therapy for cancer
patients bearing tumors with mutations in DDR proteins other than BRCA.

4.3. BRCA Mutation and BRCAness in Breast Cancer
Germline mutation of BRCA1 and BRCA2 genes are known contribute to
increased risk of hereditary, early on-set breast cancers [168]. BRCA1 mutated
breast cancer often overlapped with TNBC subgroup (from 8.5% to 28% in different patient cohorts), while BRCA2 mutation are found in 1% to 17% TNBC
patients [169, 170]. Overall, around 66% of BRCA1 mutated breast cancer are
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TNBC and average of 25% BRCA2 mutated breast cancer are TNBC. The gene
mutations that induce pathological HR deficiency, the phenomenon mimicking
the loss or mutation of BRCA1/2, are termed as “BRCAness” [171]. In general,
BRCAness tumors are more sensitive to treatment using DNA damaging agents
[171]. With the emerging of targeting defective DDR as cancer treatment strategy, breast cancer can also be grouped to BRCAness based on their mutation
of DDR genes. In breast cancer patients, around 50% of patient are identified as
BRCAness [172]. Therefore, PARP-is become an emerging targeted therapy for
breast cancer treatment, especially for TNBC [173].

4.4. PARP-i Resistant Mechanisms and Current Strategies to Overcome Resistance.
Although PARP-is have been approved by the U.S. Food and Drug Administration for BRCAm ovarian cancer and breast cancer treatment, there are
intrinsic, as well as acquired, PARP-i-resistance observed in clinical trials and
pre-clinic animal models [174, 175] (Fig. 9).
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Figure 9. PARP-i resistant mechanisms.
Several mechanisms contribute to PARP-i-resistance have been identified in
preclinical models and clinical observations, including secondary BRCA gene
mutations, loss of 53BP1, upregulation of MDR proteins, and tyrosine phosphorylation of PARP1.

Surprisingly, it is estimated that around 50% of tumors may develop acquired resistance to PARP-is based on the observation that tumors acquired
secondary mutation that restores function of BRCA1/2 [176, 177]. While
BRCAness cells are more sensitive to PARP-is, most of the PARP-is resistance
mechanisms identified are related to restoration of HR function. The HR restore
due to secondary mutations in BRCA genes were observed in majority of PARP36

is resistant cells [174-177]. Besides the secondary BRCA mutations, inactivation
of NHEJ also partially rescue BRCAness due to the low affinity of MRE11 to
DSB while lacking of competing proteins such as TP53 binding protein 1
(53BP1) [178-180]. Moreover, mechanisms that decrease interaction between
PARP1 and PARP-is also contribute to PARP-i-resistance. The upregulation of
multiple drug resistant (MDR) proteins, such as P-glycoprotein (P-gp, also
known as MDR1), induces efflux of PARP-is from cells and thus decrease
PARP-is efficacy [181-183]. In addition, MET-induced PARP1 tyrosine 907
phosphorylation can also decrease binding affinity of PARP-is to PARP1 [157].
There are several strategies under investigation to overcome PARP-i-resistance, including development of new PARP-i to avoid being substrate of MDR
proteins, reinstating BRCAness by targeting DDR proteins other than BRCA,
and inhibiting cell cycle regulating proteins to prevent undergoing HR. While
olaparib (AZD2281) is one of the substrate of MDR proteins, AZD2461, a PARPi, which is a poor substrate for MDR proteins, was developed to overcome the
MDR-mediated PARP-i-resistance [184]. Because cyclin-dependent kinases
(CDK) 1 promotes HR through phosphorylating BRCA1 [185] and CDK12 promotes transcription of HR proteins including BRCA1 [186-189]. Inhibitors of cyclin-dependent kinases are introduced to PARP-i combination strategies that decrease HR activity and re-establish BRCAness. Also, inhibitor targeting DNA
polymerase δ was developed to inhibit HR [190], and was therefore suggested
to be combined with PARP-is in overcoming PARP-i-resistance. Inhibitors abro-
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gating cell cycle checkpoint proteins and replication fork protection, such as targeting ATM, ATR, and WEE1, are under investigation as agents for overcoming
PARP-i-resistance by preventing DNA repair and inducing more replication
stress in cells[191-193]. Moreover, studies show that alternative NHEJ is utilized
in cells acquired resistance to PARP-is [194], therefore, inhibitor targeting DNA
polymerase θ is also suggested as a potential agent to overcome PARP-i-resistance [175].

5. Significance of this Study
Current strategies to overcome PARP-is resistance include inhibiting more
DNA repair pathways in combination with PARP-is to enhance DNA damages
[195], but these also affect normal tissues. To identify therapeutic agent combinations with wider therapeutic window between cancer and normal cells, we
systematically screened BRCAm breast cancer cells with acquired PARP-i resistance for commonly activated receptor tyrosine kinases, for which there are
feasible inhibitors in clinic and leveraging oncogenic addictions to these kinases
for wider therapeutic window.
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Chapter II. Materials and Methods

Cell Culture
SUM149 immortalized breast cancer cells were purchased from Asterand
Bioscience (MI, USA) and maintained in 37°C CO2 incubator with F-12K medium
(ATCC 30-2004) supplied with 5% feral bovine serum (FBS), 10 mM HEPES, 1
µg/ml hydrocortisone, 5 µg/ml insulin and 100 U/ml penicillin-100 µg/ml streptomycin (P/S). MDA-MB-231 and BT-549 cells were maintained with DMEM/F-12
medium supplied with 10% FBS and P/S. MDA-MB-468 cells were maintained
with DMEM/F-12 medium supplied with 10% FBS, P/S and L-glutamine. HCC70
and HCC1937 cells were maintained with RPMI1640 medium supplied with 10%
FBS and P/S. Except for SUM149, all cell lines were purchased from ATCC. Cell
lines were validated by short tandem repeat DNA fingerprinting using the
AmpF_STR Identifiler kit according to the manufacturer's instructions (Applied
Biosystems). Theshort tandem repeat profiles were compared with and matched
to known ATCC fingerprints (ATCC.org) and to the Cell Line Integrated Molecular Authentication database (CLIMA) version 0.1.200808 (http://bioinformatics.istge.it/clima/).

Chemicals and Regents
Methyl methanesulfonate (MMS, cat no. 129925), 3-(4,5-Dimethylthiazol2-yl)-2,5-Diphenyltetrazolium Bromide (MTT, cat no. M5655), polybrene was
purchased from Millipore-Sigma Corporate (MO, USA). Talazoparib (BMN673),
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olaparib, rucaparib, veliparib, PD173074, AZD4547 and Erdafitinib for in vitro
experiments were purchased from Selleck Chemicals (TX, USA). Concentrated
stock solutions of PARPi and kinase inhibitors were prepared with DMSO. Protease inhibitor cocktail (# B14001) and phosphatase inhibitor cocktail (#
B15001) were purchased from Biomake (Houston, TX). Para-formaldehyde
(16% stock solution, cat no.) were purchased from Electron Microscopy Sciences (Hatfield, PA, USA). pCMV-VSV-G (Addgene plasmid # 8454) and
pCMV-delta 8.9 plasmids were a gift from Dr. Robert A. Weinberg.
The primary antibodies and dilution ratio for Western blotting analysis
used in this study were: rabbit anti-FGFR3 (#ab137084; 1:2,000) and rabbit antiHistone H4 (1:1,000) from Abcam; rabbit anti-PARP (#9532S; 1:1,000) from Cell
Signaling Technology; rabbit anti-actin (#A2066; 1:5,000), mouse anti-tubulin
(#T5158; 1:5,000), mouse anti––phospho-histone H2A.X (Ser139) (#05-636;
1:1,000), mouse anti-HA (clone 12CA5) (1:1,000), and rabbit anti–phosphoFGFR (Tyr653/Tyr654) (#06-1433; 1:1000) from MilliporeSigma; rabbit antilamin B1 (#sc-374015; 1:2,000), and mouse anti-GAPDH (#sc-32233; 1:1,000)
from Santa Cruz Biotechnology.

Development of Acquired PARPi Resistant Clones
3.1 SUM149 Talazoparib Resistant Cells
As illustrated in Figure 10 below, SUM149 cells were treated with fresh
100 nM talazoparib every day for 5 consecutive days to eliminate most of the
SUM149 cells. The cells were then maintained in 15 nM talazoparib for 3 days
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before increased talazoparib concentration in culture media to 22.5 nM, 35 nM
and 50 nM. Each colony remained in 50 nM talazoparib was picked and transferred into 96-well plate with one colony for each well and were then maintained
with 50 nM talazoparib. Colonies stably proliferated in 50 nM talazoparib were
then named as BR (BMN673-Resistant) cell #01 to #31.

Figure 10. Development of talazoparib resistant SUM149 cells.
SUM149 cells were plated into 1,500 mm culture dishes a day before 100 nM
talazoparib treatment. After 5-day 100 nM talazoparib treatments, cells were
maintained in talazoparib with concentrations gradually raised from 15 - 50 nM.
After 3-days of 50 nM talazoparib incubation, single clones were then picked
and cultured in 96-well plate with 50 nM talazoparib until stable proliferation.

3.2 HCC1806-BR Cells
HCC1806 talazopairb resistant cell (HCC1806-BR) were a gift from Dr.
Khandan Keyomarsi. HCC1806-BR cells were developed by treating HCC1806
with 1 µM talazoparib continuously for 9 months.
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MTT Cell Viability Assay
Cells were seeded into 96 plate a day prior to PARP and kinase inhibitors
treatments. Number of cells seeded were adjusted for reaching 90% confluence
after 5-6 days of culture: MDA-MB-231 (1,000 cells/well), SUM149 (1,000
cells/well), SUM149-derived resistant clones (1,000 cells/well), BT549 (2,500
cells/well), HCC1937 (5,000 cells/well). Cells were treated with inhibitors indicated in different experiments in a volume of 200 µL/well and the medium containing inhibitors were refreshed every 3 days. MTT stock solution is made by
dissolving 5 mg/mL MTT in PBS. After treatment, 20 µL MTT stock solution were
added into each well and incubated for 1-2 h in 37 °C incubator. After MTT incubation, medium was removed and 50 µL DMSO were added into each well to
dissolve formazan. The quantity of formazan is measured by recording absorbance of 595 nm using microplate reader.

Whole Cell Extract Preparation
Cells were cultured until reaching 80%-90% confluence in 10-cm cell culture dish before harvested for whole cell extract preparation. Cell culture medium was removed and cells were washed with PBS before washed again with
protease inhibitor-containing PBS (PBS with 2 mM Na3VO4, 1 mM NaF and 1
mM PMSF) before scratching and centrifuging at 1,500x g for 5 min to collect
cells. Cells were then homogenized in RIPA buffer (150 mM NaCl, 1% Triton X100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.5 and PIC) with
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sonication (Bioruptor® Plus sonication device,10 sec on, 10 sec off, repeat 3 cycles) (Diagenode Inc. Denville, NJ, USA). Protein lysates were collected by centrifuging at 13,200 rpm for 10 min to remove pellet. Protein concentrations were
then determined by using BCA Protein Assay kit (Pierce, cat no. 23225).

Co-Immunoprecipitation (co-IP)
Cells were treated with chemicals indicated in each experiments before
whole cell extracts were collected for immunoprecipitation (IP). 500 µg of total
proteins were diluted to 500 µL with RIPA buffer for IP, proteins were precleaned by incubating with 1 µg IgG and 10 µL protein A/G agarose beads for 1
h at room temperature before supernatant were collected for IP after centrifuging at 2,500x g for 3 min. 2-5 µg primary antibodies were added into the samples and incubated for overnight rotating at 4 °C. For primary antibodies without
agarose pre-conjugation, 10 µL protein A/G agarose beads were added into
each sample and incubated on rotator for 1.5 h at room temperature. After incubation, agarose beads were collected by centrifuging at 2,500x g, 4 °C for 3 min
and washed 3 times by rotating at 4 °C for 5 min with IP wash buffer (150 mM
NaCl, 1% Triton X-100, 10 mM Tris, pH 7.5, 1 mM EDTA, 1 mM EGTA, 0.2 mM
Na3VO4 and protease inhibitor cocktail). IP complex were released from agarose
beads by boiling for 3 min in Laemmli buffer (2% SDS, 5% 2-mercaptoethanol,
10% glycerol, 0.005% bromophenol blue and 0.0625 M Tris, pH 6.8). After releasing, protein supernatants were collected after centrifuging at 2,500x g, 4 °C
for 5 min and were loaded for Western blotting analysis.
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Proximity ligation assay (PLA) and immunofluorescence staining
Cells were treated for 1 h with either 0.01% MMS, 0.1 µM talazoparib, or
10 µM PD173074 as indicated before fixed with 4% paraformaldehyde. 2-4
hours pre-treatment of PD173074 was introduced before combining with other
chemicals to ensure FGFR3 was inhibited while inducing DNA damages. PLA
(Duolink® In Situ Red, Sigma Aldrich) were performed following manufacture’s
instruction. Mouse anti-PARP1 (Sino Biological, #11040-MM04), rabbit antiFGFR3 (Abcam, #ab137084), and mouse anti-phospho-Histone H2A.X (Ser139)
(clone JBW301, MilliporeSigma, #05-636) primary antibodies for PLA were diluted at a ratio of 1:500 and incubated with samples overnight at 4 ℃. Immunofluorescence staining and confocal microscopy were performed as previously
described[196]. Cells were treated with either DMSO (solvent control), talazoparib (125 nM for BR#09; 250 nM for BR#17), PD173074 (10 µM), or the
combination of talazoparib and PD173074 for the time indicated. Primary antibodies were diluted in 5% BSA at a ratio of 1:500 for both anti––phospho-histone H2A.X and anti-FGFR3 and were incubated overnight. Secondary antibodies anti-mouse fluorescein isothiocyanate (FITC) and anti-rabbit Texas Red
were diluted at a 1:1,000 ratio in 5% BSA. In both immunostaining and PLA assay, images of the cells were captured and analyzed with LSM 710 laser confocal microscope and Zeiss Zen software (Carl Zeiss) and foci counting was performed using BlobFinder [197].
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Western Blotting
Cell extracts were boiled in Laemmi buffer (50 mM Tris-Cl pH 6.8, 2 %
SDS, 10 % glycerol, 5% β-mercaptoethanol, 0.05 % bromophenol blue) for 10
min before Western blotting analysis. In Western blotting analysis, proteins were
separated by electrophoresis in an 8%-10% SDS-PAGE gel with Western blotting running buffer (25 mM Tris base, 190 mM glycine, 0.1% SDS, pH 8.3) before transferred onto PVDF membrane in transfer buffer (25 mM Tris base, 190
mM glycine, 20% methanol, pH 8.3) for overnight at 4 °C. PVDF membrane
were then blocked with 5% skim milk in TBST buffer (198.18 mM Tris base, 1.5
M NaCl, 0.1% Tween 20, pH7.5) at room temperature for more than 1 h. After
blocking, the membrane was incubated with primary antibodies for overnight at
4°C before washing with TBST 3 times for 5 min each time. Primary antibodies
were diluted with 5% bovine serum albumin (BSA)/TBST at the ratio indicated in
Table 2. HRP-conjugated secondary antibodies (RocklandTM, Limerick, PA,
USA) were diluted with 5% skim milk/TBST and incubated with membrane for 1
h at room temperature before washing with TBST 3 times for 10 min each time.
Pierce™ ECL Western Blotting Substrate (Thermo Scientific™) were prepared
following manufactory’s manual. Western blotting images were captured by using ImageQuant LAS 4000 system (GE Health Care Life Sciences, Pittsburgh,
PA, USA) and quantified by using Image Studio Lite (Ver 5.2).
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Colony Formation Assay
Cells were seeded into 12-well plate at optimized densities (600 cells/well
for SUM149R #09, 800 cells/well for SUM149R #17 and 1,000 cells/well for
BT549) a day before drug treatments. After cells attached to the plate, culture
medium were refreshed with 800 µL drug-containing medium for each well.
Drug-containing medium were refreshed every 48 h for the 10-14 days incubation. For quantitation, medium were removed from each well and the wells were
washed with PBS twice before fixed with 4% paraformaldehyde at room temperature for 10 min. Colonies were stained by incubating in 0.5% crystal violet in
methanol for at least 2 h at room temperature. Excess crystal violet was washed
off under running tape water. The plate were then subjected to imaging and
quantified by using Celigo Imaging Cytometer (Nexcelom Biosciences, MA,
USA).

In Vitro Kinase Assay
Recombinant PARP1 protein (Lifespan, cat no. LS-G3996-10) and recombinant active FGFR3 kinase domains (Thermo Fisher, cat no. PV3145) are used
for in vitro kinase assay. 1 µg PARP1, 1 µg FGFR3, 0.1 mM ATP and NEBuffer
for Protein Kinases (New England Biotechnology, cat no. B6022S) were mixed
together and incubated at 30 °C for 70 min. The reaction is stopped by adding
Laemmli buffer into samples and boiled for 5 min. Samples were then subjected
to Western blotting analysis or mass spectrometry analysis as indicated. For
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Western blotting analysis, 4G10, PY20 and PY100 antibodies were mixed and
applied as primary antibody to recognize phosphorylated tyrosine.

PARP Trapping Assay
Cells were pre-treated with, 10 µM PD173074 for 2 h before 0.01% MMS
and 0.1 µM talazoparib treatment for the duration indicated in each experiment.
After treatment, cells were harvested by trypsin and washed with ice-cold PBS
twice before cell pellets were collected by 1,700 ×g centrifuge at 4 ℃. HDG150
buffer (20 mM HEPES-KOH [pH 7.4], 150 mM KCl, 0.5 mM DTT, 10% glycerol
and protease inhibitor cocktail) [198] and tight dounce tissue grinder (Wheaton
#357538) were used to isolate nucleus and cytoplasm fractions. Nuclei were collected after 1,700 ×g centrifuge at 4 ℃ and washed with 5 mL ice-cold HDG150
buffer twice. Cell nuclei were teared by using Bioruptor Twin (Diagenode, Denville, NJ) at the setting of 10-sec on, 10-sec off and 10 cycles. Chromatin-bound
fraction were collected by 20,000 ×g centrifuge at 4 ℃. After washed once with
0.2 mL ice-cold HDG150 buffer, DNA were digested using 100 U/mL micrococcal nuclease (Life Technologies #88216) in HDG150 buffer containing 5 mM calcium chloride and rotated at 20 rpm for an hour at 4 ℃ cold room. Chromatinbound proteins were then collected by 20,000 ×g centrifuge at 4 ℃ and supernatant were analyzed by Western blotting.
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Lentivirus Infection and RNA Interference
Lentiviral plasmid containing short hairpin RNA (shRNA) were purchased
from Millipore-Sigma (pLKO.1 sets), MD Anderson Cancer Center shRNA and
ORF core facility (pGIPZ sets) and Dharmacon (SMARTvector inducible
shRNA). PARP1 targeting shRNAs (shPARP1-1: TRCN0000007928; shPARP12: TRCN0000356550) and FGFR3 targeting shRNA (shFGFR3-1:
TRCN0000000371; shFGFR3-2: TRCN0000196809) were purchased from
Sigma Aldrich. Lentivirus particles were generated by transfecting HEK293T
cells with pCMV-VSV-G (Addgene plasmid # 8454), pCMV- dR8.91 and either
shRNA plasmids, PARP1 expressing plasmids or FGFR3 expressing plasmids
in a 1:3:6 ratio. Scramble shRNA control plasmid pLKO.1 (Addgene plasmid
#1864) was a gift from David Sabatini and pCMV-VSV-G was a gift from Dr. Bob
Weinberg. For lentivirus production, HEK293T cells were transfected with
pCMV-VSVG, pCMV-dR8.91and shRNA plasmid at the ratio of (1 : 5 : 10 µg). In
brief, 12 µg plasmid DNA were packaged in 18 µL SN transfection reagent for
each 10-cm plate of HEK293T. HEK293T cells were transfected with serum-free
medium for 8 h before transfecting medium were replaced by complete culture
medium. Virus particles-containing mediums were collected at 60 h post-transfection and were filtered by using 0.45 µm dish filter. The virus-containing mediums were mixed with lentivirus concentration solution (40% PEG-8000, 1.2M
NaCl in PBS) at a ratio of 1:3 and incubated at 4 °C for more than 4 h. Virus particles were then pelleted by centrifuge at 1,600x g for 1 h at 4 °C and resuspended in PBS to make virus infection solution. Cancer cell lines were cultured
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to reach 70% confluence for virus infection. Virus infection solutions were mixed
with cell culture medium and supplied with 8 µg/mL polybrene (Millipore) for
mammalian cell infection. Cells were incubated with the virus infection medium
for 72-96 h before treated with antibiotic selection medium. Stable cells were selected and maintained in the selection medium containing 1 µg/ml puromycin
(InvivoGen) or 500 µg/ml G418 (Thermo Fisher).

Cloning and mutagenesis
FGFR3-expressing plasmid pDONR223_FGFR3 (Addgene plasmid
#23933) was a gift of Dr. William Hahn and Dr. David Root [199];
pDONR223_FGFR3_K650E (Addgene plasmid #82187) was a gift from Dr.
Jesse Boehm, Dr. William Hahn, and Dr. David Root [200]. FGFR3 was subcloned from pDONR223-FGFR3 into pCDH-CMV-MCS-EF1-Neo (System Biosciences) by amplifying the FGFR3 open reading frame with polymerase chain
reaction. 3xFlag-tag was inserted by oligomer annealing. The same cloning
strategies were used for generating FGFR3K650E-expressing plasmid. HA-tagged
PARP1 expression plasmid was described in our previous study [157].
FGFR3K508R-, PARP1Y158F-, and PARP1Y176F-expressing plasmids were generated using site-directed mutagenesis polymerase chain reaction and HA-PARP1
plasmid [157].

Table 2. Sequences of primers for PARP1 mutagenesis.
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Primer Name
PARP1 Y158E-F
PARP1 Y158E-R
PARP1 Y158F-F
PARP1 Y158F-R
PARP1 Y176E-F
PARP1 Y176E-R
PARP1 Y176F-F
PARP1 Y176F-R
pCDH-EF1-F

Sequence
TGATTGACCGCTGGGAACATCCAGGCTG
CAAAGCAGCCTGGATGTTCCCAGCGGTCAAT
TAGGCATGATTGACCGCTGGTTTCATCCAGGCTG
CTTGACAAAGCAGCCTGGATGAAACCAGCGGTC
GTTTCCGGCCCGAGGAAAGTGCGAGTCAG
GAGCTGACTCGCACTTTCCTCGGGCCGGAA
GTTTCCGGCCCGAGGAAAGTGCGAGTCAG
CTTGAGCTGACTCGCACTAAACTCGGGCCGGAA
CTCCACGCTTTGCCTGACCCTGCTT

Comet Assay
Cells were seeded into 60-mm cell culture dish at least 18 h before reaching 60% confluence for treatments. Cells were treated with 0.01% MMS, 100 nM
talazoparib, and 10 µM PD173074 as indicated. When releasing cells from
MMS, culture medium was removed and cells were washed with ice-cold PBS
twice before adding fresh prepared inhibitor-containing medium for DNA repair.
Alkaline comet assay was performed as described previously [201]. In brief,
cells were harvested and diluted to 2x105 cells/ml in PBS, and were embedded
in 1.2% low-melting point agarose gel at 1:1 ratio. 80 µl mixture were applied to
a 24 mm x 40 mm area and the slide was immersed in alkaline lysis buffer (10
mM Tris, 2.5 M NaCl, 100 mM EDTA, 1% Triton X-100, 10% DMSO, 1% sodium
lauryl sarcosinate, pH 10.0) overnight. DNA damages were further digested with
2U formamidopyrimidine [fapy]-DNA glycosylase (fpg) (New England BioLabs, #
M0240S) for 1 h before electrophoresis (22V, 300 mA, 20 min). Comet Olive
moment were measured using CometScore v1.5 (TriTek).

50

Xenograft Mouse Models
Animal studies were performed following an MD Anderson Cancer Center
Institutional Animal Care and Use Committee–approved protocol. Female nude
mice were purchased from the MD Anderson Cancer Center Department of Experimental Radiation Oncology. For BR#09 and BR#17 xenograft mouse models, two million cells were mixed with 50% (v/v) growth factor reduced matrigel
matrix (Corning) and inoculated into the mammary fat pads of a 6 to 8-week-old
female nude mouse. For 4T1 model, female Balb/c mice were purchased from
Jackson Laboratory. A total of 50,000 4T1 cells were mixed with matrigel matrix
and inoculated into the mammary fat pad of a 6-week-old female Balb/c mouse.
Inhibitors at the concentrations indicated in each experiment were dissolved in
vehicle solvent containing 10% dimethylacetamide (Sigma-Aldrich), 5% Kolliphor HS 15 (Sigma-Aldrich), and 85% phosphate-buffered saline [202]. Inhibitor
treatment started when tumor volume reached a mean of 120 mm3. Mice were
treated using oral gavage daily for 20 days followed by 3 days with no drugs to
prevent severe weight loss. After the first cycle, treatment was continued on a
schedule of 6 days on and 1 day off. Mouse weight and tumor volume were
measured 3 times every week. Tumor volume was estimated using the following
formula: volume (mm3) = length (mm) × width (mm) × 0.5 width (mm), where
length is the longest axis of the tumor. Mice were killed using CO2 when tumor
volume reached 2,000 mm3. Mouse cardiac blood were collected and used for
blood chemical tests that performed by veterinarians in MD Anderson Cancer
Center Department of Veterinary Medicine and Surgery.
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Tyrosine 158 Phosphorylated PARP1 Antibody Generation
Mouse anti-phospho-PARP1 Y158 antisera were generated by immunize
20 mice with phospho-PARP1-Y158 KLH hot peptide (KLH-C-EKPQLGMIDRWpY-HPG-S-FVKNREE) once every 2 weeks. Binding affinities specificities of the
antisera were evaluated by using ELISA and Western dot blot with hot peptide
(C-EKPQLGMIDRW-pY-HPG-S-FVKNREE) and cold peptide (C-EKPQLGMIDRW-Y-HPG-S-FVKNREE) and Western blotting. The homemade antibodies
were prepared by Ms. Hung-Ling Wang and Dr. Shao-Chun Wang in Center for
Molecular Medicine, China Medical University.

Statistics
For Western blotting signal quantifications, signal intensities were analyzed by using Image Studio Lite (version 5.2) (LI-COR Biosciences). Signals of
PARP1, PAR, FGFR3, and phosphorylated FGFR were first normalized to
house-keeping proteins (tubulin, actin, or GAPDH) of each sample before being
normalized to the control groups. Every independent experiment repeat is quantified individually. Fold changes in Western blot signals were analyzed by a nonparametric Friedman test using the GraphPad Prism 8.0 software. A p value
less than 0.05 was considered statistically significant. *, p < 0.05; **, p < 0.002;
***, p < 0.001. CI experiments were designed according to the Chou-Talalay
method [203], and results were calculated using Compusyn software
(http://www.combosyn.com).
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Chapter III.
Fibroblast Growth Factor Receptor (FGFR) Inhibition Reinstates PARP Inhibitor Anti-tumor Efficacy in Breast Cancer
with Acquired Resistance by Prolonging PARP Trapping

Fibroblast Growth Factor Receptors (FGFR) in Breast Cancer
Fibroblast growth factor (FGF) induced FGFR pathways are important in
regulating cellular homeostasis. The FGF-FGFR pathways are known involving
in multiple cellular regulations including cell proliferation, angiogenesis, cell differentiation, migration and survival (reviewed in). FGFR is a family of receptor
tyrosine kinases (RTKs) containing 4 members, FGFR1, 2, 3, and 4. The FGFR
members share conserved structure, including three extracellular immunoglobulin (Ig) domains, a single transmembrane (TM) helix, cytosolic tyrosine kinase
(TK) domain and a short carboxy-terminal tail (reviewed in). There are 18 fibroblast growth factors (FGF) identified as ligand for FGFRs (reviewed in [204]).
For FGFR1-3, alternative splicing results in generation of receptor isoforms, band c- variants. FGFR1-3 IIIb and IIIc are generated from alternative exon used
in ligand binding domain, therefore, ligand specificity of FGFR as well as biological functions may largely altered in IIIb and IIIc variants. Previous study shows
that FGFR1-4 and their IIIb and IIIc variants can be activated at various efficiencies of different FGFs. Despite ligand-stimulated activation, unliganded FGFR
can still form receptor dimers [ref]. By using FRET assays, Sarabipour and Hristova concluded that FGFR3 has highest unligand dimer among FGFR1-4 and,
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even at low receptor concentration (10 receptors/µm2), 50% of FGFR3 still form
unliganded dimer.
FGFR alterations are found in multiple cancer types, including breast cancer. Using cBioPortal to analyze data from TCGA database showed that alterations of FGFR1-4 are found in multiple patient breast cancer patient cohorts
(Fig. 11A) and is correlated with worse overall survival (p-value 0.007) (Fig.
11B).

(A)
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(B)

Figure 11. FGFR alterations in multiple breast cancer patients’ cohorts.
(A) FGFR1-4 gene alteration type and frequency in different breast cancer cohorts. Green: gene mutation; Red: gene amplification; Blue: gene deletion; Purple: gene fusion; Dark grey: multiple alterations. (B) Overall survival KaplanMeier estimate plot of 857 cases of FGFR1-4 altered patients with 334 patient
deceased and median survival of 135.3 months; 5608 patients without FGFR1-4
alteration and 1555 patient deceased, medium survival 165.4 months.

There are around 10% of breast cancer patient exhibit FGFR1 gene amplification (chromosome 8p11-12), and this amplification is found predominantly in
ER-positive breast cancers. Amplification of this region is positively correlated to
lower metastasis-free survival, higher oncogene addiction and invasion of cancer cells. FGFR2 is amplified in 5%-10% of breast cancer tumors. In vitro study
show that overexpressed FGFR2 contribute to resistance of cancer cells to
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FGFR inhibitor. Mutations of FGFR2 has been reported in multiple cancer types,
R203C, N550K, S588C and K660M are found in breast cancer. FGFR3 amplification is rare in breast cancer (around 1%) (reviewed in [205]). Despite low mutation rate of FGFRs in breast cancer, the aberrant activation of FGFR is one of
the known antiangiogenic therapy-resistance mechanisms, and FGFR inhibition
contributes to enhance endocrine therapy in breast cancer [205]. Therefore,
FGFR inhibition is still one of the potential targeted therapies suitable for breast
cancer treatment, and there are multiple FGFR inhibitors currently under clinical
trial investigations in different solid tumors (Table 3).

Table 3. FGFR Inhibitors in Clinical Studies.
Inhibitor
AZD4547

Targets
FGFR1
FGFR2
FGFR3
KDR

Company
AstraZeneca

Dovitinib
(TKI-258)

FLT3
c-Kit
FGFR3
VEGFR1
VEGFR2
VEGFR3

Novartis
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Clinical Trial Identify Number
Ph I/II: NCT01824901 (Lung cancer)
Ph I/II: NCT01202591 (ER+ breast
cancer)
Ph II: NCT01795768 (Gastric cancer,
Oesophageal cancer, Breast
cancer, SCLC)
Ph II: NCT01457846 (Gastro-oesophageal junction cancer, gastric
Cancer
Ph II/III: NCT02965378 (SCLC)
Ph I/II: NCT01791985 (ER+ breast
cancer)
Ph I/II: NCT01921673 (Gastric cancer)
Ph II: NCT01719549 (Gastric cancer)
Ph II: NCT01732107 (Bladder cancer)
Ph II: NCT01676714 (NSCLC, Colorectal cancer)
Ph II: NCT01831726 (Tumor)
Ph II: NCT00958971 (HER2- breast
cancer)
Ph II: NCT01379534 (Endometrial cancer)
Ph II: NCT00790426 (Urothelial cancer)

Erdafitinib
(JNJ42756493)

FGFR1
FGFR2
FGFR3
FGFR4

Janssen

BGJ398

FGFR1
FGFR2
FGFR3
FGFR4

Novartis

Lucitanib
(E-3810)

FGFR1
FGFR2
FGFR3
VEGFR1
VEGFR2
VEGFR3
PDGFRα
PDGFRβ
FGFR1
FGFR2
FGFR3
FGFR4

Clovis Oncology

FGFR1
FGFR2
FGFR3
FGFR4
PDGFRα
VEGFR2
c-Src
c-Kit
Abl

ARIAD Pharmaceuticals

Rogaratinib

Ponatinib

Bayer
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Ph I: NCT03238196 (ER+/HER2breast cancer)
Ph I: NCT03825484 (Advanced cancers)
Ph III: NCT03390504 (Urothelial cancer)
Ph II: NCT02699606 (Urothelial cancer, Esophageal cancer, Cholangiocarcinoma)
Ph II: NCT02365597 (Urothelial cancer)
Ph II: NCT03827850 (Lung cancer)
Ph I: NCT01703481 (Advanced or Refractory Solid Tumors or Lymphoma)
Ph II: NCT03210714 (Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma)
Ph I/II: NCT03473743 (Urothelial cancer)
Ph II: NCT02160041 (Solid Tumor, Hematologic Malignancies)
Ph I: NCT01004224 (Solid Tumor)
Ph Ib: NCT01928459 (Solid Tumor)
Ph I: NCT01697605 (Tumors)
Ph II: NCT02053636 (ER+ breast cancer)
Ph I/II: NCT01283945 (Solid tumor)
Ph II: NCT02202746 (Breast cancer)
Ph II: NCT02109016 (Lung cancer)

Ph I: NCT03517956 (Advanced solid
tumor)
Ph I: NCT01976741 (Neoplasm)
Ph I: NCT03788603 (Neoplasm)
Ph II: NCT03762122 (NSCLC)
Ph II: NCT02272998 (Advanced cancers)
Ph II/III: NCT01761747 (NSCLC, Head
and neck cancer)
Ph II: NCT02265341 (Advanced biliary
cancer)

Pemigatinib

FGFR1
FGFR2
FGFR3

Incyte

Derazantinib
ARQ-087

FGFR1
FGFR2
FGFR3
FGFR4
RET
DDR2
PDGFRβVEG
FR
c-KIT
FGFR1
FGFR2
FGFR3
FGFR4
VEGFR1
VEGFR2
VEGFR3
VEGFR4
PDGFRα
PDGFRβ
Src
Lyn
FGFR1
FGFR2
FGFR3
FGFR4
FGFR1
FGFR2
FGFR3
FGFR4
FGFR3

ArQule

FGFR1
FGFR2
FGFR3
FGFR4
FGFR1
VEFGR1
VEGFR2
Flk1

Nintedanib

TAS-120

Debio 1347

LY3076226
PRN1371

Brivanib

Ph I: NCT03822117 (Advanced cancers)
Ph II: NCT03011372 (Myeloproliferative neoplasms)
Ph II: NCT02872714 (Urothelial Cancer)
Ph I/II: NCT01752920 (Advanced solid
tumor)

Centro
Nacional de
Investigaciones Oncologicas
CARLOS III

Ph II: NCT01948141 (NSCLC)
Ph I: NCT02619162 (Breast cancer)

Taiho Oncology

Ph I/II: NCT02052778 (Cholangiocarcinoma, Brain Tumor, Urothelial
Cancer)

Debiopharm

Ph II: NCT03834220 (Solid tumor)
Ph I: NCT01948297 (Solid tumor)
Ph II: NCT03344536 (Breast cancer)

Eli Lilly
Principia Biopharma

Ph I: NCT02529553 (Advanced cancer)
Ph I: NCT02608125 (Solid tumor,
Urothelial cancer)

Bristol-Myers
Squibb

Ph II: NCT01367275 (Colorectal cancer)
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ASP5878

FGFR1
FGFR2
FGFR3
FGFR4

Astellas
Pharma

Ph I: NCT02038673 (Solid tumors)

*Due to limited space, Ph I studies are not listed in this Table unless it focuses
on breast cancer.

FGFR3 is highly activated in cells with acquired PARP-i resistance
To screen for activated RTKs between PARP-i-sensitive and resistant
cells with similar genetic background, we developed a panel of 31 cell lines with
acquired talazoparib-resistance (BR#01-#31) from the PARP-i–sensitive,
BRCA1-mutated TNBC cell line SUM149 (Fig. 10). The half maximal inhibitory
concentration (IC50) of talazoparib in the pool of BR cells was more than 100fold than that in parental cells in colony formation assays (SUM149: 0.5 nM; BR:
50 nM, Fig. 12) and in MTT assays (SUM149: 1 nM; BR: 10 µM, Fig. 13).

Figure 12. SUM149-BR is more resistant to talazoparib than SUM149 parental cell in colony formation assay.
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Cells were seeded into 6-well plate and incubated overnight before treated with
various concentrations of talazoparib for 10-14 days. Colonies were then stained
with crystal violet and quantified. The number of colonies in the well without talazoparib treatment was designated to represent 100% relative colony forming
rate. The number of colonies in wells treated with talazoparib were normalized
to that of untreated well for calculating relative colony forming rate in response
to talazoparib. Mean ± S.D. from 3 independent experiments were shown in the
quantified figure.

Figure 13. SUM149-BR is more resistant to talazoparib than SUM149 parental cell in MTT assay.
Cells plated into a 6-well plate and incubated overnight before treated with various concentrations of talazoparib for 5-6 days. Cell survival was then measured
by using the value of optical density at 595 nm in MTT assays, the wells without
talazoparib treatment were designated as 100% survival. Mean ± S.D. from 3 independent experiments were shown in the quantified figure.

As expected, the pool of BR cells showed cross-resistance to various
PARP-is, including olaparib, rucaparib, and veliparib, with resistance capacity
similar to that of intrinsic PARP-i resistant TNBC cells, including MDA-MB-231,
BT-549, MDA-MB-468, HCC70, and HCC1937 (Fig. 14).
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Figure 14. SUM149-BR cell shows resistance to four different PARP-is at a
level comparable to known PARP-i-resistant TNBC cell lines.
The survival of cells in response to various concentrations of PARP-is indicated
were measured by MTT assay. The cell survival curves were than used for calculating IC50 by using GraphPad Prism 8.0. Mean ± S.D. from 3 independent experiments were shown in the quantified figure.

We further determined the IC50 of four PARP-is in individual BR cells, and
the cells showed a range of responses to these PARP-is; overall, the BR cells
were more resistant to talazoparib and olaparib than to rucaparib and veliparib
(Fig. 15).
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Figure 15. The IC50 of BR cells to PARP-is.
Cells were treated with various concentrations of PARP-is as indicated for 6
days before cell survival was analyzed by MTT assay. Fold (x) of IC50 was compared to that of SUM149 parental cell (SUM).

PARP-i–mediated cytotoxicity greatly relies on the involvement of PARP1
in DDR [206], to accentuate the rationale of including PARP-is in treatment strategy, we investigated the contribution of PARP1 to PARP-i-induced cytotoxicity in
SUM149, BR#09, and BR#17 cells. We found that knocked-down endogenous
PARP1 expression (PARP1KD) in these cells, compared with the control cells
carrying non-targeting shRNA, caused at least 10-fold more resistant to talazoparib (Fig. 16), indicating that PARP1 is still required for PARP-is-induced cytotoxicity in SUM149 and BR cells. Therefore, we deduced that PARP-i resistance in these cells is related to PARP1-mediated pathways, but is not due
mainly to PARP-i efflux or loss of PARP1 [183, 206-209], and that PARP-is remain as reasonable therapeutic agent for BR cells.
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Figure 16. Knocking down PARP1 enhances talazoparib resistance in
SUM149 and BR cells.
Endogenous PARP1 expression was knocked-down using two different short
hairpin RNAs (shRNA) against PARP1 (shPARP1). Non-targeting shRNA was
introduced as control (Ctrl). SUM149 and BR cells expressing control shRNA or
shPARP1-2 were subjected to talazoparib treatment at various concentrations,
and cell survival was measured by using MTT assay.

We selected 15 BR cells in order to identify common RTK targets, and
sought specific RTK activations harbored in the majority of these cells, but not in
SUM149 parental cell, with phospho-RTK antibody arrays (Fig. 17). Quantification data of the arrays showed that FGFR, IGFR and EGFR families were the
most phosphorylated RTK families in BR cells, with phosphorylated FGFR3 had
the highest prevalence of array signals that were at least 10-fold higher than in
parental SUM149 cells (Fig. 17).
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Figure 17. Antibody arrays of RTK activation in SUM149 and BR cells.
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Cells indicated were treated with dimethyl sulfoxide (DMSO) or 100 nM talazoparib overnight and harvested for RTK antibody array analysis. Signal intensities on each array were normalized to the mean signal intensity of positive reference spots on each array and compared with the signal intensity of respective
spots on SUM149 DMSO-treated array.

We validated the array data by Western blotting and found that, in about
50% of BR cells, FGFR3 phosphorylation and FGFR3 expression were higher
than that in parental SUM149 cells (Fig. 18).

66

Figure 18. Expressions of phosphorylated FGFR3 and total FGFR3 proteins are higher in around half of the BR cells.
SUM149 and the 31 BR cells were treated with 100 nM talazoparib overnight
before harvested for Western blotting analysis. Actin was chosen to serve as
loading control. Signals of phosphorylated FGFR (p-FGFR) and FGFR3 were
normalized to actin and then normalized to that of SUM149 (1-fold). Three independent repeats were performed and the quantitation histograms indicate mean
± S.D.
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Furthermore, FGFR3 was also activated in acquired talazoparib resistant
cells developed from HCC1806 TNBC cell (Fig. 19).

Figure 19. FGFR3 is activated in HCC1806-BR cells.
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HCC1806-BR cell is more resistant to olaparib, talazoparib, and rucaparib than
HCC1806 parental cells. Antibody arrays of RTK activation in HCC1806 parental
cell and HCC1806-BR cells were performed with cells treated overnight with 1
µM talazoparib.

These results indicated that phosphorylated FGFR3 is common among
acquired PARP-i–resistant TNBC cells. Therefore, we chose two BR cells
(BR#09 and BR#17) that had high FGFR3 expression for studying the effects of
FGFR3 on PARP-i resistance. To validate the involvement of FGFR3 in PARP-i
resistance, we knocked-down endogenous FGFR3 expression (FGFR3KD) in
BR#09 and BR#17 cells. As expected, FGFR3KD strengthened talazoparib sensitivity in these cells, and that FGFR3KD cells rescued with wild-type FGFR3
(FGFR3WT) exhibited restored resistance to talazoparib (Fig. 20).

Figure 20. FGFR3 contributes to talazoparib resistance in BR cells.
FGFR3 expression was knocked-down by shRNA in SUM149, BR#09, and
BR#17 cells, and the expression of FGFR3 were examined by Western blotting.
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Survival rate of the cells indicated in response to talazoparib was analyzed by
MTT assay after 6 days of talazoparib treatment.

FGFR inhibition impedes DNA repair efficiency and has synergism with
PARP-is
To elucidate role of FGFR3 in PARP-i-resistance, we first examined
whether DNA damages can induce phosphorylation of FGFR3 by using alkylating agent methyl methanesulfonate (MMS) to damage DNA [207]. Indeed, both
BR#09 and BR#17 cells elevated FGFR3 phosphorylation more than SUM149
cell in response to MMS and talazoparib treatment, and the FGFR phosphorylation can be inhibited by FGFR-is (Fig. 21).
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Figure 21. FGFR-is inhibited talazoparib-induced FGFR phosphorylation.
Cells were treated with either 5 µM PD173074 (PD), erdafitinib (JNJ), or
AZD4547 (AZD) for 4 h, and then further exposed to 100 nM talazoparib (Tala)
and 0.01% MMS in combination with the FGFR-is indicated for another hour before harvested for Western blotting analysis.

While MMS induced similar amount of DNA damage in these cells, we
found that BR cells have fewer DNA damages left than SUM149 at 3 h postMMS treatment (Fig. 22).
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Figure 22. BR cells have higher DNA repair efficiency than SUM149.
SUM149, BR#09, and BR#17 cells were treated with 0.01% MMS for 40 min
(+MMS) to induce DNA damages. The cells were then released from MMS by
refreshing cell culture medium to allow DNA repair for 3 h. The untreated group
(-MMS) were harvested at the same time with the groups repaired after 3 h.
DNA damages were then measured by alkaline comet assay using olive moment metric.
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Because the confocal microscope analysis showed that FGFR3 co-localized with γH2AX DNA break foci (Fig. 23), we further investigated the effect of
FGFR inhibition on DNA repair.

Figure 23. Co-localization of FGFR3 and γH2AX in cell nucleus.
BR#17 cell were treated with 250 nM talazoparib and 0.01% MMS FGFR-is for
an hour before fixed and subjected to immunofluorescence staining with antibodies against FGFR3 (TexasRed, red) and γH2AX (FITC, green). DNA was
counterstained with DAPI (4′6-diamidino-2-phenylindole) (blue). Z-stack images were captured using confocal microscope.
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The γH2AX foci staining also show that, in absence of MMS, γH2AX foci
formed in talazoparib treated cells is similar to that in cells treated with talazoparib and PD173074 combination (Fig. 24). Moreover, γH2AX foci significantly decreased from 4 to 8 hour treatment (p-value < 0.001) in untreated cells
or cells treated with either talazoparib or PD173074 alone, but the amount of
γH2AX foci remains unrepaired from 4 to 8 in combination treated group (Fig.
24).
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Figure 24. Combination of talazoparib and PD173074 delays repair of
γH2AX foci.
BR#17 cells were treated for 1 hour with 0.01% MMS combined with 250 nM
talazoparib (Tala) and 10 µM PD173074 (PD) as indicated. MMS was removed
and cells were cultured in fresh culture medium (Ctrl), talazoparib, or PD173074
either alone or in combination for 4 h and 8 h before cells were fixed for immunofluorescence staining. DNA strand break γH2AX foci were detected using
anti-γH2AX antibody (FITC, green) and DNA was counterstained with DAPI
(blue). The γH2AX foci in each cell nucleus were counted using Blobfinder and
the statistical analysis was performed using ANOVA, data from at least 150 individual cells were shown in dot, and the histogram showed mean ± 95% confident interval.

The same phenomenon was also observed in comet assay with MMS-induced DNA damages. We induced DNA damage in BR cells with MMS in the
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presence of either talazoparib, PD173074, or combination of talazoparib and
PD173074, and we found that combination of PD173074 and talazoparib did not
induce more DNA damages than talazoparib treatment in comet assay (Fig. 25).

Figure 25. Combination of talazoparib and PD173074 does not increase
DNA damage induction.
BR#09 cells were treated with 0.01% MMS, 100 nM talazoparib, and 10 µM
PD173074 either alone or in combination for 1 h before harvested for alkaline
comet assay. Among MMS treated groups, DNA damages in tail was quantified
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using olive moment and normalized to that of talazoparib treated group. Statistical analysis was performed with ANOVA, data from at least 100 individual cells
were shown in dot, and the mean ± standard deviation (S.D.) were shown.

Interestingly, while most of cells in control group eliminated DNA damage
at 3 h after MMS removal, we found that BR cells in talazoparib treated group
had similar unrepaired DNA damages as in PD173074 group, and that more
DNA damages were left in cells repaired in combination of talazoparib and
PD173074 (Fig. 26). Our comet assay and γH2AX foci staining data suggest
that the combination treatment does not induce more DNA damages than talazoparib treatment, but the combination of talazoparib and PD173074 delays
DNA repair efficiency, and thus, the combination may be more cytotoxic because it induces sustained burden of DNA breaks.
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Figure 26. Combination of talazoparib and PD173074 delays DNA repair.
BR#09 cells were treated with 0.01% MMS, 100 nM talazoparib, and 10 µM
PD173074 either alone or in combination for 1 h. MMS was then removed and
cells were incubated in talazoparib and PD173074 as indicated for 3 h before
harvested for alkaline comet assay. DNA damages in tail was quantified using
olive moment and normalized to that of talazoparib treated group. Statistical
analysis was performed with ANOVA, data from at least 100 individual cells
were shown in dot, and the mean ± standard deviation (S.D.) were shown.

We further examined the efficacies of combining PARP-is and FGFR-is in
eliminating BR#09 and BR#17 cells. We evaluated the synergy between FGFRis and PARP-is by measuring the combination index (CI) in these cells, in general, CI below 0.8 represents synergistic effect between inhibitors and CI below
0.3 indicates a strong synergism [210]. Considering the potential for study of this
approach in clinical trials, we paired inhibitors developed by the same pharmaceutical companies, e.g. talazoparib combined with PD173074; olaparib combined with AZD4547. Using colony formation assay, we demonstrated that, in
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BR#09 cell, combination of talazoparib and PD173074 had a moderate synergism (CI ranging from 0.3 to 0.9); in BR#17 cell, strong synergism between talazoparib and PD173074 was observed (CI below 0.07) (Fig. 27).
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Figure 27. CI of talazoparib and PD173074 in BR#09 and BR#17 cells measured by colony formation assay.
Cells were treated with talazoparib and PD173074 at the concentrations indicated for 10-12 days, and then cells were fixed for colony formation assay.
Number of colony formed was normalized to that in control group without talazoparib and PD173074 treatment, mean ± S.D. from at least 3 independent repeats were shown in histogram. CI was calculated using colony formation data
obtained in the colony formation assay.

Because MTT assay is relatively more efficient in screening multiple ratios
of drug combination than colony formation assay, we utilized MTT assay to evaluate synergism of PARP-is and FGFR-is BR and TNBC cells. In BR cells, the
combination of talazoparib and PD173074 had a CI between 0.2 and 0.8 when
eliminating more than 80% of the cells (Fa greater than 0.8) (Fig. 28), and the
combination of olaparib and AZD4547 had a CI between 0.1 and 0.5 (Fig. 28).

Figure 28. CI of the talazoparib and PD173074 combination or the olaparib
and AZD4547 combination in multiple BR cells.
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Cells were treated with various concentrations of talazoparib and PD173074
combinations or olaparib and AZD4547 combinations for 6 days before cell survival was measured by MTT assay. CI was then calculated by Compusyn software and MTT data of cell survival in response to treatments. Fa, fraction affected.

CI between 0.2 and 0.8 can also be reached in BT-549 and MDA-MB-157
cells with combinations of olaparib and AZD4547 (Fig. 29), suggesting the synergy of this combination is not limited to the BR cells we developed.

Figure 29. CI of the olaparib and AZD4547 combination in BT-549 and
MDA-MB-157 cells.
Cells were treated with various concentrations of olaparib and AZD4547 combinations for 4 days before cell survival was measured by MTT assay. CI was
then calculated by Compusyn software and MTT data of cell survival in response to treatments. Fa, fraction affected.
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Inhibiting FGFR-mediated PARP1 Y158 phosphorylation reverses resistance to PARP-is
Since FGFR3 enhances PARP-i-resistance and FGFR inhibition affect
DNA repair efficiency, we investigated whether FGFR3 exist in PARP1-interacting protein complex. We found that FGFR3 can be co-immunoprecipitated with
PARP1 (Fig. 30), and our proximity ligation assay (PLA) data suggest FGFR3
and PARP1 can interact in cell nucleus (Fig. 31). Moreover, through PLA analysis, we found that the PLA signals of PARP1 and FGFR3 was less in cells
treated with combination of talazoparib and PD173074 than in cells treated with
either inhibitor alone (Fig. 31).

Figure 30. Co-immunoprecipitation of PARP1 and FGFR3.
82

SUM149 and BR#09 cells were treated with 100 nM talazoparib (PARPi) and 10
µM PD173074 (FGFRi) as indicated before harvested for PARP1 immunoprecipitation. For each sample, 500 µg total protein lysate was used for immunoprecipitation and 40 µg total protein were used for detecting target proteins in the cell
lysate (input). The immunoprecipitated complex were then subjected to analyze
the presence of FGFR3 by Western blotting.
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Figure 31. Combination of talazoparib and PD173074 decreases interaction
between PARP1 and FGFR3.
FGFR3 and PARP1 PLA assays were performed with BR#09 and BR#17 cells
treated with either 0.01% MMS, 100 nM talazoparib and 10 µM PD173074 either
alone or in combination. Antibodies against FGFR3 and PARP1 were used and
PLA signals (red) was detected using Duolink red assay and quantified by using
Blobfinder. Phalloidin (green) was used to detect cytoskeleton and DNA was
counterstained with DAPI (blue). Mean ± 95% confident interval of the number of
PLA signals in each cell nucleus were shown in histogram. Individual cells were
shown as dot and statistical analysis was performed using ANOVA with n > 100
in each group.

Followed our PLA results, we further hypothesized that FGFR3 may phosphorylate PARP1. Our in vitro kinase assay and mass spectrum analysis
showed that FGFR phosphorylates PARP1 only at Y158 and Y176 amino acids
(Fig. 32), which were predicted by motif scanning database to be phosphorylated by FGFR3 and FGFR1, respectively (Table 4).
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Figure 32. FGFR-mediated tyrosine phosphorylation of PARP1.
His-tagged PARP1 recombinant protein was incubated with activated FGFR kinase domain before half the samples were subjected to Western blotting analysis. Phosphorylated tyrosine residues were detected by antibodies against phospho-tyrosine (clone 4G10, PY20, and PY100) in Western blotting. The other half
of the samples were separated on sodium dodecyl sulfate gel, and the p120 protein band was cut from the gel and sent for mass spectrum analysis. Phosphorylated tyrosine residues identified through mass spectrometry were aligned with
PARP1 protein sequence and marked in red.
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Table 4. Potential FGFR-mediated tyrosine phosphorylation sites on
PARP1 predicted by motif scanning database

Motif scanning database GPS 5.0 (http://gps.biocuckoo.cn)

We generated Y-to-phenylalanine (F) mutated PARP1 to mimic un-phosphorylated PARP1 and further examined contributions of these phosphorylation
sites to PARP-i resistance and found that PARP1Y158F BR cells had talazoparib
IC50 lower than that of PARP1WT cells in MTT assay (Fig. 33). However,
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PARP1Y176F did not show a significant impact on cell survival compared to
PARP1WT in response to talazoparib treatment (Fig. 33).
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Figure 33. Effect of PARP1Y158F and PARP1Y176F mutants on cell survival in response to talazoparib.
PARP1 knock-down (PARP1KD) BR#09 and BR#17 cells were exogenously expressed with hemagglutinin (HA)-tagged vector control (Neo), wild-type PARP1
(WT), and PARP1Y158F and PARP1Y176F mutants as indicated. Exogenous
PARP1 expression was examined by Western blotting. Cells were treated with
various concentrations of talazoparib for 6 days before cell survival rate was
measured by MTT assay.

Using monoclonal antibody against Y158 phosphorylated PARP1 (p-Y158
PARP1), we showed that p-Y158 PARP1 can be diminished by treating BR cell
with PD173074 (Fig. 34), and that synergism between talazoparib and
PD173074 decreased in BR cells carrying PARP1Y158F mutant (Fig. 35). These
results suggest the p-Y158-mediated cellular functions can indeed be inhibited
by FGFR inhibition and contribute to FGFR-mediated PARP-i-resistance. Thus,
we focused on studying DDR alteration between PARP1WT and PARP1Y158F mutants.
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Figure 34. PARP1 Y158 phosphorylation can be inhibited by PD173074.
BR#17 cells were treated with MMS, 100 nM talazoparib (Tala), and 10 µM
PD173074 (PD) as indicated before harvested for Western blotting analysis to
detect p-Y158 PARP1 (pY158), PARP1, phosphorylated FGFR3 (pFGFR3),
FGFR3, and actin.

Figure 35. Synergism between talazoparib and PD173074 is affected by
PARP1 Y158 phosphorylation.
CI of talazoparib and PD173074 in BR#17 cells expressing wild-type PARP1
(WT) or PARP1Y158F mutant (Y158F) with 6-day MTT assays.
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We found that MMS is still capable of increasing PARylation signals in
both PARP1WT and PARP1Y158F expressing BR cells and that PARP1WT and
PARP1Y158F cells had similar PARP1 expression and PAR signals (Fig. 36), suggesting that PARylation activity of PARP1 is not compromised, and that PARP-iresistance mediated by p-Y158 PARP1 does not positively correlate with
PARP1 enzymatic activity.

Figure 36. PARP1 Y158F mutant does not affect MMS-induced PARylation
in BR cells.
BR#09 and BR#17 cells expressing either wild-type PARP1 (PARP1-WT) or
PARP1Y158F mutant were treated with 0.01% MMS for 1 h. PARP1 expression,
PARylation (PAR), and tubulin were detected by Western blotting. PAR signal
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intensity were normalized to tubulin signal intensity before compared to treated
groups to wild-type PARP1 expressing cells treated with MMS (1-fold). Histograms show the mean ± S.D. from 3 independent repeats.

Therefore, we further examined the effect of p-Y158 PARP1 on PARP
trapping. We found that more PARP1 was bound to chromatin in PARP1Y158Fexpressing cells than in PARP1WT-expressing cells (Fig. 37), supporting our hypothesis that FGFR3 mediates PARP-i resistance by phosphorylating PARP1 at
the Y158 residue.

Figure 37. Effect of PARP1Y158F on PARP-trapping.
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PARP1 knock-down cells expressing vector, wild-type PARP1, and
PARP1Y158F mutants were treated with 100 nM talazoparib and 0.01% MMS
for 40 min. Cells were harvested after removal of talazoparib and MMS for 0, 30,
or 60 min and subjected to cell fractionation. Chromatin-bound PARP1 was then
analyzed by Western blotting. PARP1 signal intensities were normalized to histone H4 and compared with that of PARP1 wild-type cells treated with talazoparib and MMS (PARP1-WT, 0 min). Mean ± S.D. from 3-5 individual repeats
were shown in histogram and analyzed with ANOVA.

Moreover, we found that PD173074 can also prolonged talazoparib-induced PARP1 trapping in BR cells (Fig. 38). Therefore, we concluded that
FGFR3 mediates PARP-i-resistance through phosphorylating PARP1 at Y158
residue to decrease PARP trapping caused by PARP-is.
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Figure 38. Effect of PD173074 on PARP-trapping.
As indicated, cells were pre-treated with 10 µM PD173074 for at least 2 h in
FGFRi treated groups before treatment of 100 nM talazoparib and 0.01% MMS
for another 40 min. Cells were harvested after removal of MMS and talazoparib
for 0, 30, or 60 min and subjected to cell fractionation. Chromatin-bound PARP1
was then analyzed by Western blotting. PARP1 signal intensities were normalized to histone H4 and compared with that of cells treated with talazoparib and
MMS (MMS +, PARPi +, FGFRi +, 0 min). Mean ± S.D. from 3-5 individual repeats were shown in histogram and analyzed with ANOVA.

Clinical application potent of targeting FGFR in PARPi-resistant TNBC
Xenograft mouse models with BR cells were employed to validate synergism of FGFR-i and PARP-i in vivo. Talazoparib treatment inhibited tumor

93

growth in the SUM149 model but not in BR#09 or BR#17 models (Fig. 39), confirming that BR cells remain PARP-i resistant in mouse models.

Figure 39. Talazoparib inhibits tumor growth in SUM149, but not in BR xenograft mouse models.
Two millions of SUM149, BR#09 and BR#17 cells were injected to the mammary fat pad of nude mice. Vehicle and talazoparib (0.25 m/k/d) daily treatment
began at the time that the tumors reached an average size of 100 mm3. For
each model, 4-5 mice were included in each treatment group, and the figures
show mean and S.D. of the tumors for 33 days of treatment.
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For each inhibitor used in mouse treatment, concentration similar to or
lower than those of the equivalent recommended dose for human [211-214]. As
shown in both BR#09 and BR#17 xenograft mouse models, olaparib did not inhibit tumor growth as vehicle treatment, and AZD4547 slightly inhibited tumor
growth only in BR#17 (p-value = 0.0192 at day 57). However, the combination of
olaparirb and AZD4547 significantly inhibited tumor growth in both models (For
BR#09, p-value < 0.0001 compared to vehicle and single agent treatments; for
BR#17, p-value = 0.0046 compared to AZD4547 and p-value < 0.0001 to vehicle and olaparib treatment) (Fig. 40). Therefore, combination of olaparib and
AZD4547 prolonged animal survival in both models (Fig. 40). Meanwhile, animal
weight loss was not observed in both models (Fig. 40), suggesting the toxicity is
tolerable during the treatment.

95

Figure 40. Synergy of FGFR-i and PARP-i in xenograft models.
BR#09 (n=5) and BR#17 (n=4) xenograft mouse models were treated with vehicle, olaparib (40 m/k/d), AZD4547 (8 m/k/d) either alone or in combination
through oral gavage. Tumor volumes were measured at least twice a week and
statistical analysis were performed using ANOVA (Upper panel). Survival days
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of xenograft mouse models treated with olaparib and AZD4547 as described
(Middle panel). Body weight (g) of mice treated (Lower panel).

Since PD173074 has not been investigated in clinical trial, we titrated its
concentration for animal use by treating BR#09 xenograft mice with either 10
mg/kg/d or 20 mg/kg/d PD173074 with or without talazoparib. With tumors harvested after 3 days of treatments, we found that talazoparib induced FGFR3
phosphorylation, and the talazopairib-induced FGFR phosphorylation were inhibited by PD173074 at 10 mg/kg/d, and was inhibited further by 20 mg/kg
PD173074 to less than the basal levels in the vehicle-treated control group (Fig.
41). However, 1/3 of mice treated with 20 mg/kg PD173074 combined with talazoparib experienced more than 10% weight loss (Fig. 41). Therefore, we chose
15 mg/kg/d PD173074 for our further animal studies to ensure FGFR inhibition
while minimizing toxicity.
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Figure 41. PD173074 treatment dose titration in xenograft mouse model.
BR#09 xenograft mice (5-6 mice per group) were treated with PD173074 at 10
mg/kg or 20 mg/kg daily for 3 days before tumors were harvested for Western
blotting analysis. Signal intensities of phosphorylated FGFR (p-FGFR) were normalized to that of tubulin and compared with the mean intensity in a vehicle98

treated group and shown in the quantitation panel (mean ± S.D.). Mouse body
weight change (mean ± S.D.) after treatment was normalized to that of the
mouse before treatment.

As expected, talazoparib and PD173074 single agent treatments did not
inhibit tumor growth in both BR#09 and BR#17 models, while the combination of
talazoparib and PD173074 significantly inhibited tumor growth (p-value < 0.0001
in both models) and prolonged animal survival (Fig 42).

Figure 42. Combination of talazoparib and PD173074 suppress tumor
growth and prolongs survival of BR xenograft mouse models.
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Tumor growth and survival of the BR#09 (n=5) and BR#17 (n=6) xenograft models in response to talazoparib (0.25 m/k/d) and PD173074 (15 m/k/d) alone or in
combination through oral gavage. Tumor volumes were measured 2-3 times
every week.

To investigate the toxicity of the talazoparib and PD173074 combination,
we chose the syngeneic 4T1 model to test the effects of talazoparib and
PD173074 alone and in combination. In the 4T1 mice, the talazoparib and
PD173074 combination inhibited tumor growth more than the talazoparib and
PD173074 single-agent treatments did for two weeks of treatment before mice
were sacrificed for toxicity tests. Blood chemical tests showed that the blood
urea nitrogen (BUN), alanine aminotransferease (ALT), and aspartate aminotransferase (AST) levels in these animals were within the range of normal
Balb/c mice (Fig. 43), indicating that the kidney and liver functions of these mice
were not damaged by the treatments.
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Figure 43. Blood chemical test of 4T1 mouse treated with talazoparib and
PD173074.
Blood were collected by cardiac puncture after 12 days of treatment, and the
concentrations of alanine aminotransferase (ALT), aspartate aminotransferase
(AST), and blood urea nitrogen (BUN) were measured. Dot lines indicate the
concentration of ALT, AST and BUN reported in North American colonies of
Charles river BALC/C mouse (https://animalab.eu/sites/all/pliki/produktydopobrania/balb_c_Mouse_clinical_pathology_data.pdf).

As PARP-is are approved as maintenance therapy for platinum drug-sensitive tumors and the PARP-is shared similar resistance mechanisms with platinum resistance, we collected patient-derived xenograft (PDX) models with
known PARP-is or platinum resistance as PARP-is are recently approved for
breast cancer and there are limited breast cancer patients treated with long-term
PARP-is. We further correlated p-FGFR signals to talazoparib resistance and
platinum resistance using tissues of patient-derived xenograft (PDX) models developed from TNBC patients [202]. In 13 TNBC PDX tissues’ IHC staining, we
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found that talazoparib and platinum resistant PDX models has a slightly higher
H-score of p-FGFR (H-score 251.4 ± 51.1) than the sensitive models (p-FGFR
H-score 191.7 ± 48.6, p-value 0.0862) (Fig. 44).

Figure 44. Immunohistochemistry staining of phosphorylated FGFR in
TNBC PDX tumors.
TNBC PDX tissue microarray was collected by Dr. Coya Tapia and the response
of these PDX models to talazoparib and platinum agents were performed by laboratory of Dr. Funda Meric-Bernstam . Immunohistochemistry staining and H-
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score calculation was performed by Dr. Weiya Xia. The statistical p-value is calculated using Mann-Whitney test (two-tailed) in GraphPad Prism 8.

Moreover, we also found significant higher of p-FGFR H-score in platinum
resistant ovarian cancer PDX models (H-score 186.5 ± 49.6) than the sensitive
models (H-score 120.0 ± 13.9, p-value 0.0093) (Fig. 45).This correlation suggests that p-FGFR and p-Y158 PARP1 have the potential to serve as biomarkers in indicating patients with FGFR-mediated PARP-i-resistance.
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Figure 45. Immunohistochemistry staining of phosphorylated FGFR in
Ovarian Cancer PDX tumors.
Ovarian cancer PDX tissue microarray was collected, and the patient responses
to platinum agents were provided by laboratory of by Dr. Jinsong Liu. Immunohistochemistry staining and H-score calculation was performed by Dr. Weiya
Xia. The statistical p-value is calculated using Mann-Whitney test (two-tailed) in
GraphPad Prism 8.
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Chapter IV. Discussion
In this study, we concluded that inhibition of FGFR3 reinstates PARP-i sensitivity
through prolonging PARP trapping. We found FGFR phosphorylates PARP1 at Y158 amino
acid, and that PARP1 Y158 non-phosphorylated mutant (PARP1Y158F) was trapped longer
than PARP1WT in BR cells, indicating this FGFR-mediated PARP1 phosphorylation contributes to resolve PARP trapping in these cells. The prolonged PARP trapping decreases efficiency of DNA repair and hence increase DNA damage burden in cells. We also demonstrated that FGFR-i and PARP-i synergistically inhibit growth of tumor cells in animal models, and that the toxicity of combination is manageable. Furthermore, using PDX models, we
showed that p-FGFR and p-Y158 PARP1 can serve as biomarkers for stratifying patients for
FGFR-i and PARP-i combination treatment.
Previous artificial introduced CRISPR-Cas9 mutagenesis screen study showed that
PARP1 ZF1 domain F44I mutation contributes to PARP-i-resistance because it is spared
from PARP trapping [215]. Since structural studies showed that ZF1 and ZF2 domains form
a functional unit to recognize DNA strand break [159], Y158F mutation-induced prolong of
PARP trapping may be explained from aspect of protein conformation. Structurally, Y158
amino acid locates adjacent to PARP1 ZF2 domain’s zinc ion binding residues (C125, C128,
H159 and C162) and the DNA interacting residues (L151/I156)[216, 217], indicating that
Y158 may also involve in protein structure stabilization. Therefore, there is possibility that pY158 PARP1 disrupts the dissociation of PARP1 from DNA by altering the structural stability of the PARP1 dimer. This protein structure aspect can also provide a reason for our finding that Y176F mutation did not enhance PARP-i sensitivity, because Y176 locates away

105

from DNA binding core residues. However, detailed studies regarding impacts of p-Y158 on
PARP1 conformation and dimerization should be further pursued.
We previously reported that MET also contributes to PARP inhibitor resistance
through phosphorylating PARP1[157]. However, FGFR3 and MET phosphorylate PARP1 at
different domains, and thus, the two RTKs have different impacts on DDR and may enhance
therapeutic efficacies of PARP-is in different patient populations. MET phosphorylates
PARP1Y907 at catalytic domain, and thus increasing PARP1 enzymatic activity while decreasing interaction between PARP-i and PARP1[157]. In contrast, we found that inhibition of
FGFR decreases solving of PARP-trapping through phosphorylate PARP1Y158 at DNA-binding domain, but this p-Y158 PARP1 has similar enzymatic activity to its non-phosphorylated
mutant (PARP1Y158F). Therefore, we deduced that FGFR-i and PARP-i combination will benefit patients bearing tumors that solve PARP-i-induced PARP trapping efficiently, and that
combination of MET inhibitor and PARP-is will benefit patients carrying tumors in which
PARP-is failed to inhibit PARP1 enzymatic activity. We further FGFR-is may be more suitable that MET inhibitors in the PARP-is combination strategies for patients with acquired resistance to PARP trapping-inducing PARP-is such as talazoparib and olaparib. In the future,
we aim on developing efficient p-Y158 PARP1 and p-FGFR screening method and promoting targeted PARP-i combination therapeutic strategies using the biomarker-kinase pairs we
discovered as references to guide personalized PARP-i therapy in cancer treatment.
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Appendix

1. Plasmid Map and Sequence of pCDH-EF1-HA-PARP1-Neo

Amino Acid Sequence of HA-PARP1
(GenBank: AAH37545.1)
Met Y P Y D V P D Y A A E S S D K L Y R V E Y A K S G R A S C K K C S E S I
P K D S L R Met A I Met V Q S P Met F D G K V P H W Y H F S C F W K V G H S I R
HPDVEVDGFSELRWDDQQKVKKTAEAGGVTGKGQDGIGSK

107

A E K T L G D F A A E Y A K S N R S T C K G C Met E K I E K G Q V R L S K K Met V
D P E K P Q L G Met I D R W Y H P G C F V K N R E E L G F R P E Y S A S Q L K
GFSLLATEDKEALKKQLPGVKSEGKRKGDEVDGVDEVAKKK
SKKEKDKDSKLEKALKAQNDLIWNIKDELKKVCSTNDLKELL
I F N K Q Q V P S G E S A I L D R V A D G Met V F G A L L P C E E C S G Q L V F K
S D A Y Y C T G D V T A W T K C Met V K T Q T P N R K E W V T P K E F R E I S Y L
KKLKVKKQDRIFPPETSASVAATPPPSTASAPAAVNSSASA
D K P L S N Met K I L T L G K L S R N K D E V K A Met I E K L G G K L T G T A N K A
S L C I S T K K E V E K Met N K K Met E E V K E A N I R V V S E D F L Q D V S A S T
KSLQELFLAHILSPWGAEVKAEPVEVVAPRGKSGAALSKKS
K G Q V K E E G I N K S E K R Met K L T L K G G A A V D P D S G L E H S A H V L E
KGGKVFSATLGLVDIVKGTNSYYKLQLLEDDKENRYWIFRS
W G R V G T V I G S N K L E Q Met P S K E D A I E H F Met K L Y E E K T G N A W H
SKNFTKYPKKFYPLEIDYGQDEEAVKKLTVNPGTKSKLPKP
V Q D L I K Met I F D V E S Met K K A Met V E Y E I D L Q K Met P L G K L S K R Q I
Q A A Y S I L S E V Q Q A V S Q G S S D S Q I L D L S N R F Y T L I P H D F G Met K
K P P L L N N A D S V Q A K A E Met L D N L L D I E V A Y S L L R G G S D D S S K
DPIDVNYEKLKTDIKVVDRDSEEAEIIRKYVKNTHATTHNAY
DLEVIDIFKIEREGECQRYKPFKQLHNRRLLWHGSRTTNFA
G I L S Q G L R I A P P E A P V T G Y Met F G K G I Y F A D Met V S K S A N Y C H T
S Q G D P I G L I L L G E V A L G N Met Y E L K H A S H I S K L P K G K H S V K G L
GKTTPDPSANISLDGVDVPLGTGISSGVNDTSLLYNEYIVYD
I A Q V N L K Y L L K L K F N F K T S L W Stop
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HA Tag-ZnF1-ZnF2-NLS-ZnF3-BRCT-WGR-PARP a-helical-Catalytic Domain
Met: M, Methionine
Y : Phospho-tyrosine detected by mass spectrometry
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